1db1 › Citations

The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand.

Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D
Mol Cell 5 173-9 (2000)
Cited: 419 times
EuropePMC logo PMID: 10678179

Abstract

The action of 1 alpha, 25-dihydroxyvitamin D3 is mediated by its nuclear receptor (VDR), a ligand-dependent transcription regulator. We report the 1.8 A resolution crystal structure of the complex between a VDR ligand-binding domain (LBD) construct lacking the highly variable VDR-specific insertion domain and vitamin D. The construct exhibits the same binding affinity for vitamin D and transactivation ability as the wild-type protein, showing that the N-terminal part of the LBD is essential for its structural and functional integrity while the large insertion peptide is dispensable. The structure reveals the active conformation of the bound ligand and allows understanding of the different binding properties of some synthetic analogs.

Reviews - 1db1 mentioned but not cited (7)

  1. Endogenously produced nonclassical vitamin D hydroxy-metabolites act as "biased" agonists on VDR and inverse agonists on RORα and RORγ. Slominski AT, Kim TK, Hobrath JV, Oak ASW, Tang EKY, Tieu EW, Li W, Tuckey RC, Jetten AM. J Steroid Biochem Mol Biol 173 42-56 (2017)
  2. Vitamin D and Its Synthetic Analogs. Maestro MA, Molnár F, Carlberg C. J Med Chem 62 6854-6875 (2019)
  3. Structural considerations of vitamin D signaling. Molnár F. Front Physiol 5 191 (2014)
  4. Molecular Illustration in Research and Education: Past, Present, and Future. Goodsell DS, Jenkinson J. J Mol Biol 430 3969-3981 (2018)
  5. Vitamin D and Its Receptor from a Structural Perspective. Rochel N. Nutrients 14 2847 (2022)
  6. Alternative binding sites at the vitamin D receptor and their ligands. Mutchie TR, Yu OB, Di Milo ES, Arnold LA. Mol Cell Endocrinol 485 1-8 (2019)
  7. Allosteric Antagonism of the Pregnane X Receptor (PXR): Current-State-of-the-Art and Prediction of Novel Allosteric Sites. Kamaraj R, Drastik M, Maixnerova J, Pavek P. Cells 11 2974 (2022)

Articles - 1db1 mentioned but not cited (61)

  1. Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. Svensson S, Ostberg T, Jacobsson M, Norström C, Stefansson K, Hallén D, Johansson IC, Zachrisson K, Ogg D, Jendeberg L. EMBO J 22 4625-4633 (2003)
  2. Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. Tocchini-Valentini G, Rochel N, Wurtz JM, Mitschler A, Moras D. Proc Natl Acad Sci U S A 98 5491-5496 (2001)
  3. Products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activity. Slominski AT, Janjetovic Z, Fuller BE, Zmijewski MA, Tuckey RC, Nguyen MN, Sweatman T, Li W, Zjawiony J, Miller D, Chen TC, Lozanski G, Holick MF. PLoS One 5 e9907 (2010)
  4. Structure of the full human RXR/VDR nuclear receptor heterodimer complex with its DR3 target DNA. Orlov I, Rochel N, Moras D, Klaholz BP. EMBO J 31 291-300 (2012)
  5. A system-level investigation into the mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for cardiovascular disease treatment. Li X, Xu X, Wang J, Yu H, Wang X, Yang H, Xu H, Tang S, Li Y, Yang L, Huang L, Wang Y, Yang S. PLoS One 7 e43918 (2012)
  6. Alternatively spliced isoforms of the human constitutive androstane receptor. Auerbach SS, Ramsden R, Stoner MA, Verlinde C, Hassett C, Omiecinski CJ. Nucleic Acids Res 31 3194-3207 (2003)
  7. Identification of an alternative ligand-binding pocket in the nuclear vitamin D receptor and its functional importance in 1alpha,25(OH)2-vitamin D3 signaling. Mizwicki MT, Keidel D, Bula CM, Bishop JE, Zanello LP, Wurtz JM, Moras D, Norman AW. Proc Natl Acad Sci U S A 101 12876-12881 (2004)
  8. A nonclassical vitamin D receptor pathway suppresses renal fibrosis. Ito I, Waku T, Aoki M, Abe R, Nagai Y, Watanabe T, Nakajima Y, Ohkido I, Yokoyama K, Miyachi H, Shimizu T, Murayama A, Kishimoto H, Nagasawa K, Yanagisawa J. J Clin Invest 123 4579-4594 (2013)
  9. A structural model of the constitutive androstane receptor defines novel interactions that mediate ligand-independent activity. Dussault I, Lin M, Hollister K, Fan M, Termini J, Sherman MA, Forman BM. Mol Cell Biol 22 5270-5280 (2002)
  10. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Marshall TG, Lee RE, Marshall FE. Theor Biol Med Model 3 1 (2006)
  11. Evolution of the bile salt nuclear receptor FXR in vertebrates. Reschly EJ, Ai N, Ekins S, Welsh WJ, Hagey LR, Hofmann AF, Krasowski MD. J Lipid Res 49 1577-1587 (2008)
  12. Hydrogen/deuterium exchange reveals distinct agonist/partial agonist receptor dynamics within vitamin D receptor/retinoid X receptor heterodimer. Zhang J, Chalmers MJ, Stayrook KR, Burris LL, Garcia-Ordonez RD, Pascal BD, Burris TP, Dodge JA, Griffin PR. Structure 18 1332-1341 (2010)
  13. Correlation between secosteroid-induced vitamin D receptor activity in melanoma cells and computer-modeled receptor binding strength. Kim TK, Wang J, Janjetovic Z, Chen J, Tuckey RC, Nguyen MN, Tang EK, Miller D, Li W, Slominski AT. Mol Cell Endocrinol 361 143-152 (2012)
  14. Storage function of cartilage oligomeric matrix protein: the crystal structure of the coiled-coil domain in complex with vitamin D(3). Ozbek S, Engel J, Stetefeld J. EMBO J 21 5960-5968 (2002)
  15. Vitamin D receptor (VDR) regulation of voltage-gated chloride channels by ligands preferring a VDR-alternative pocket (VDR-AP). Menegaz D, Mizwicki MT, Barrientos-Duran A, Chen N, Henry HL, Norman AW. Mol Endocrinol 25 1289-1300 (2011)
  16. Vitamin D analogs combined with 5-fluorouracil in human HT-29 colon cancer treatment. Milczarek M, Filip-Psurska B, Swiętnicki W, Kutner A, Wietrzyk J. Oncol Rep 32 491-504 (2014)
  17. A single point mutation in ecdysone receptor leads to increased ligand specificity: implications for gene switch applications. Kumar MB, Fujimoto T, Potter DW, Deng Q, Palli SR. Proc Natl Acad Sci U S A 99 14710-14715 (2002)
  18. Improved docking, screening and selectivity prediction for small molecule nuclear receptor modulators using conformational ensembles. Park SJ, Kufareva I, Abagyan R. J Comput Aided Mol Des 24 459-471 (2010)
  19. A Residue-Resolved Bayesian Approach to Quantitative Interpretation of Hydrogen-Deuterium Exchange from Mass Spectrometry: Application to Characterizing Protein-Ligand Interactions. Saltzberg DJ, Broughton HB, Pellarin R, Chalmers MJ, Espada A, Dodge JA, Pascal BD, Griffin PR, Humblet C, Sali A. J Phys Chem B 121 3493-3501 (2017)
  20. The evolution of farnesoid X, vitamin D, and pregnane X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) and other non-mammalian species. Krasowski MD, Ai N, Hagey LR, Kollitz EM, Kullman SW, Reschly EJ, Ekins S. BMC Biochem 12 5 (2011)
  21. A molecular description of ligand binding to the two overlapping binding pockets of the nuclear vitamin D receptor (VDR): structure-function implications. Mizwicki MT, Menegaz D, Yaghmaei S, Henry HL, Norman AW. J Steroid Biochem Mol Biol 121 98-105 (2010)
  22. Carborane-based design of a potent vitamin D receptor agonist. Otero R, Seoane S, Sigüeiro R, Belorusova AY, Maestro MA, Pérez-Fernández R, Rochel N, Mouriño A. Chem Sci 7 1033-1037 (2016)
  23. Network pharmacology-based prediction of the multi-target capabilities of the compounds in Taohong Siwu decoction, and their application in osteoarthritis. Zheng CS, Xu XJ, Ye HZ, Wu GW, Li XH, Xu HF, Liu XX. Exp Ther Med 6 125-132 (2013)
  24. New insights into Vitamin D sterol-VDR proteolysis, allostery, structure-function from the perspective of a conformational ensemble model. Mizwicki MT, Bula CM, Bishop JE, Norman AW. J Steroid Biochem Mol Biol 103 243-262 (2007)
  25. HDX reveals the conformational dynamics of DNA sequence specific VDR co-activator interactions. Zheng J, Chang MR, Stites RE, Wang Y, Bruning JB, Pascal BD, Novick SJ, Garcia-Ordonez RD, Stayrook KR, Chalmers MJ, Dodge JA, Griffin PR. Nat Commun 8 923 (2017)
  26. Quercetin Directly Interacts with Vitamin D Receptor (VDR): Structural Implication of VDR Activation by Quercetin. Lee KY, Choi HS, Choi HS, Chung KY, Lee BJ, Maeng HJ, Seo MD. Biomol Ther (Seoul) 24 191-198 (2016)
  27. Analysis of the interaction of calcitriol with the disulfide isomerase ERp57. Gaucci E, Raimondo D, Grillo C, Cervoni L, Altieri F, Nittari G, Eufemi M, Chichiarelli S. Sci Rep 6 37957 (2016)
  28. Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model. Moore RG, Lange TS, Robinson K, Kim KK, Uzun A, Horan TC, Kawar N, Yano N, Chu SR, Mao Q, Brard L, DePaepe ME, Padbury JF, Arnold LA, Brodsky A, Shen TL, Singh RK. PLoS One 7 e34443 (2012)
  29. 3DIANA: 3D Domain Interaction Analysis: A Toolbox for Quaternary Structure Modeling. Segura J, Sanchez-Garcia R, Tabas-Madrid D, Cuenca-Alba J, Sorzano CO, Carazo JM. Biophys J 110 766-775 (2016)
  30. Computational prediction and analysis of breast cancer targets for 6-methyl-1, 3, 8-trichlorodibenzofuran. Chitrala KN, Yeguvapalli S. PLoS One 9 e109185 (2014)
  31. Ouabagenin is a naturally occurring LXR ligand without causing hepatic steatosis as a side effect. Tamura S, Okada M, Kato S, Shinoda Y, Shioda N, Fukunaga K, Ui-Tei K, Ueda M. Sci Rep 8 2305 (2018)
  32. PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models. Kawar N, Maclaughlan S, Horan TC, Uzun A, Lange TS, Kim KK, Hopson R, Singh AP, Sidhu PS, Glass KA, Shaw S, Padbury JF, Vorsa N, Arnold LA, Moore RG, Brard L, Singh RK. Genes Cancer 4 524-534 (2013)
  33. Applications of the Vitamin D sterol-Vitamin D receptor (VDR) conformational ensemble model. Mizwicki MT, Bishop JE, Norman AW. Steroids 70 464-471 (2005)
  34. Chemical synthesis, biological activities and action on nuclear receptors of 20S(OH)D3, 20S,25(OH)2D3, 20S,23S(OH)2D3 and 20S,23R(OH)2D3. Brzeminski P, Fabisiak A, Slominski RM, Kim TK, Janjetovic Z, Podgorska E, Song Y, Saleem M, Reddy SB, Qayyum S, Song Y, Tuckey RC, Atigadda V, Jetten AM, Sicinski RR, Raman C, Slominski AT. Bioorg Chem 121 105660 (2022)
  35. Cytosolic sequestration of the vitamin D receptor as a therapeutic option for vitamin D-induced hypercalcemia. Rovito D, Belorusova AY, Chalhoub S, Rerra AI, Guiot E, Molin A, Linglart A, Rochel N, Laverny G, Metzger D. Nat Commun 11 6249 (2020)
  36. Agonist and antagonist binding to the nuclear vitamin D receptor: dynamics, mutation effects and functional implications. Yaghmaei S, Roberts C, Ai R, Mizwicki MT, Chang CE. In Silico Pharmacol 1 2 (2013)
  37. IDENTIFICATION OF VDR ANTAGONISTS AMONG NUCLEAR RECEPTOR LIGANDS USING VIRTUAL SCREENING. Teske K, Nandhikonda P, Bogart JW, Feleke B, Sidhu P, Yuan N, Preston J, Goy R, Han L, Silvaggi NR, Singh RK, Bikle DD, Cook JM, Arnold LA. Nucl Receptor Res 1 101076 (2014)
  38. Molecular Mechanism of Cancer Susceptibility Associated with Fok1 Single Nucleotide Polymorphism of VDR in Relation to Breast Cancer Raza S, Dhasmana A, Bhatt MLB, Lohani M, Arif JM. Asian Pac J Cancer Prev 20 199-206 (2019)
  39. Unintended specificity of an engineered ligand-binding protein facilitated by unpredicted plasticity of the protein fold. Day AL, Greisen P, Doyle L, Schena A, Stella N, Johnsson K, Baker D, Stoddard B. Protein Eng Des Sel 31 375-387 (2018)
  40. Identification of Novel Non-secosteroidal Vitamin D Receptor Agonists with Potent Cardioprotective Effects and devoid of Hypercalcemia. Khedkar SA, Samad MA, Choudhury S, Lee JY, Zhang D, Thadhani RI, Karumanchi SA, Rigby AC, Kang PM. Sci Rep 7 8427 (2017)
  41. Synthesis and Biological Activities of Some New Benzotriazinone Derivatives Based on Molecular Docking; Promising HepG2 Liver Carcinoma Inhibitors. El Rayes SM, Ali IAI, Fathalla W, Mahmoud MAA. ACS Omega 5 6781-6791 (2020)
  42. A human vitamin D receptor mutant activated by cholecalciferol. Ousley AM, Castillo HS, Duraj-Thatte A, Doyle DF, Azizi B. J Steroid Biochem Mol Biol 125 202-210 (2011)
  43. An integrative approach to develop computational pipeline for drug-target interaction network analysis. Bansal A, Srivastava PA, Singh TR. Sci Rep 8 10238 (2018)
  44. Anti-Colon Cancer Activity of Dietary Phytochemical Soyasaponin I and the Induction of Metabolic Shifts in HCT116. Xia X, Lin Q, Zhao N, Zeng J, Yang J, Liu Z, Huang R. Molecules 27 4382 (2022)
  45. Covalent labeling of nuclear vitamin D receptor with affinity labeling reagents containing a cross-linking probe at three different positions of the parent ligand: structural and biochemical implications. Kaya T, Swamy N, Persons KS, Ray S, Mohr SC, Ray R. Bioorg Chem 37 57-63 (2009)
  46. Design, Synthesis, Evaluation and Structure of Allenic 1α,25-Dihydroxyvitamin D3 Analogs with Locked Mobility at C-17. Fraga R, Len K, Lutzing R, Laverny G, Loureiro J, Maestro MA, Rochel N, Rodriguez-Borges E, Mouriño A. Chemistry 27 13384-13389 (2021)
  47. Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors In Vivo. Khazan N, Kim KK, Hansen JN, Singh NA, Moore T, Snyder CWA, Pandita R, Strawderman M, Fujihara M, Takamura Y, Jian Y, Battaglia N, Yano N, Teramoto Y, Arnold LA, Hopson R, Kishor K, Nayak S, Ojha D, Sharon A, Ashton JM, Wang J, Milano MT, Miyamoto H, Linehan DC, Gerber SA, Kawar N, Singh AP, Tabdanov ED, Dokholyan NV, Kakuta H, Jurutka PW, Schor NF, Rowswell-Turner RB, Singh RK, Moore RG. J Med Chem 65 6039-6055 (2022)
  48. Seco-B-Ring Steroidal Dienynes with Aromatic D Ring: Design, Synthesis and Biological Evaluation. Szybinski M, Brzeminski P, Fabisiak A, Berkowska K, Marcinkowska E, Sicinski RR. Int J Mol Sci 18 E2162 (2017)
  49. A multidisciplinary approach disclosing unexplored Aflatoxin B1 roles in severe impairment of vitamin D mechanisms of action. Persico M, Sessa R, Cesaro E, Dini I, Costanzo P, Ritieni A, Fattorusso C, Grosso M. Cell Biol Toxicol 39 1275-1295 (2023)
  50. A nuclear receptor HR96-related gene underlies large trans-driven differences in detoxification gene expression in a generalist herbivore. Ji M, Vandenhole M, De Beer B, De Rouck S, Villacis-Perez E, Feyereisen R, Clark RM, Van Leeuwen T. Nat Commun 14 4990 (2023)
  51. An Assay on the Possible Effect of Essential Oil Constituents on Receptors Involved in Women's Hormonal Health and Reproductive System Diseases. Sakhteman A, Pasdaran A, Afifi M, Hamedi A. J Evid Based Integr Med 25 2515690X20932527 (2020)
  52. Electrosmog and autoimmune disease. Marshall TG, Heil TJR. Immunol Res 65 129-135 (2017)
  53. Analysis of vitamin D receptor binding affinities of enzymatically synthesized triterpenes including ambrein and unnatural onoceroids. Ueda D, Matsuda N, Takaba Y, Hirai N, Inoue M, Kameya T, Abe T, Tagaya N, Isogai Y, Kakihara Y, Bartels F, Christmann M, Shinada T, Yasuda K, Sato T. Sci Rep 14 1419 (2024)
  54. Conservative mutageneic perturbations of amino acids connecting helix 12 in the 1alpha,25(OH)2-D3 receptor (VDR) to the ligand cause significant transactivational effects. Bula CM, Bishop JE, Norman AW. J Steroid Biochem Mol Biol 103 286-292 (2007)
  55. Functional Analysis of VDR Gene Mutation R343H in A Child with Vitamin D-Resistant Rickets with Alopecia. Tseng MH, Huang SM, Lo FS, Huang JL, Cheng CJ, Lee HJ, Lin SH. Sci Rep 7 15337 (2017)
  56. Metabolomics- and systems toxicology-based hepatotoxicity mechanism of Sophorae Tonkinensis Radix et Rhizoma in rats. Yu D, Shao Z, Fu Y, Tang X, Chen Q, Deng Z. Front Pharmacol 13 1015008 (2022)
  57. Sunscreen Ingredient Octocrylene's Potency to Disrupt Vitamin D Synthesis. Abdi SAH, Ali A, Sayed SF, Nagarajan S, Abutahir, Alam P, Ali A. Int J Mol Sci 23 10154 (2022)
  58. The conformational dynamics of H2-H3n and S2-H6 in gating ligand entry into the buried binding cavity of vitamin D receptor. Tee WV, Ripen AM, Mohamad SB. Sci Rep 6 35937 (2016)
  59. The vitamin D receptor as a potential target for the toxic effects of per- and polyfluoroalkyl substances (PFASs): An in-silico study. Azhagiya Singam ER, Durkin KA, La Merrill MA, Furlow JD, Wang JC, Smith MT. Environ Res 217 114832 (2023)
  60. Vitamin D Analogs Bearing C-20 Modifications Stabilize the Agonistic Conformation of Non-Responsive Vitamin D Receptor Variants. Belorusova AY, Rovito D, Chebaro Y, Doms S, Verlinden L, Verstuyf A, Metzger D, Rochel N, Laverny G. Int J Mol Sci 23 8445 (2022)
  61. Vitamin D receptor (VDR) on the cell membrane of mouse macrophages participates in the formation of lipopolysaccharide tolerance: mVDR is related to the effect of artesunate to reverse LPS tolerance. Zhang Y, Zhou J, Hua L, Li P, Wu J, Shang S, Deng F, Luo J, Liao M, Wang N, Pan X, Yuan Y, Zheng Y, Lu Y, Huang Y, Zheng J, Liu X, Li X, Zhou H. Cell Commun Signal 21 124 (2023)


Reviews citing this publication (112)

  1. Nuclear hormone receptors and gene expression. Aranda A, Pascual A. Physiol Rev 81 1269-1304 (2001)
  2. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Physiol Rev 96 365-408 (2016)
  3. Vitamin D metabolism, mechanism of action, and clinical applications. Bikle DD. Chem Biol 21 319-329 (2014)
  4. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Kliewer SA, Goodwin B, Willson TM. Endocr Rev 23 687-702 (2002)
  5. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, Manson JE, Murad MH, Kovacs CS. Endocr Rev 33 456-492 (2012)
  6. Molecular mechanisms of vitamin D action. Haussler MR, Whitfield GK, Kaneko I, Haussler CA, Hsieh D, Hsieh JC, Jurutka PW. Calcif Tissue Int 92 77-98 (2013)
  7. Vitamin D and diabetes. Mathieu C, Gysemans C, Giulietti A, Bouillon R. Diabetologia 48 1247-1257 (2005)
  8. PXR, CAR and drug metabolism. Willson TM, Kliewer SA. Nat Rev Drug Discov 1 259-266 (2002)
  9. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Norman AW, Mizwicki MT, Norman DP. Nat Rev Drug Discov 3 27-41 (2004)
  10. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Mathieu C, Adorini L. Trends Mol Med 8 174-179 (2002)
  11. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Bourguet W, Germain P, Gronemeyer H. Trends Pharmacol Sci 21 381-388 (2000)
  12. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Huang P, Chandra V, Rastinejad F. Annu Rev Physiol 72 247-272 (2010)
  13. Vitamin D signaling, infectious diseases, and regulation of innate immunity. White JH. Infect Immun 76 3837-3843 (2008)
  14. The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). Pike JW, Meyer MB. Endocrinol Metab Clin North Am 39 255-69, table of contents (2010)
  15. New insights into the mechanisms of vitamin D action. Christakos S, Dhawan P, Liu Y, Peng X, Porta A. J Cell Biochem 88 695-705 (2003)
  16. Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. di Masi A, De Marinis E, Ascenzi P, Marino M. Mol Aspects Med 30 297-343 (2009)
  17. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. Haussler MR, Haussler CA, Bartik L, Whitfield GK, Hsieh JC, Slater S, Jurutka PW. Nutr Rev 66 S98-112 (2008)
  18. Physiological functions of Vitamin D in adipose tissue. Abbas MA. J Steroid Biochem Mol Biol 165 369-381 (2017)
  19. New perspectives on the vitamin D binding protein. Chun RF. Cell Biochem Funct 30 445-456 (2012)
  20. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment. Tebben PJ, Singh RJ, Kumar R. Endocr Rev 37 521-547 (2016)
  21. The pleiotropic actions of vitamin D. Lin R, White JH. Bioessays 26 21-28 (2004)
  22. Vitamin D metabolism and signaling in the immune system. White JH. Rev Endocr Metab Disord 13 21-29 (2012)
  23. Evolution of our understanding of vitamin D. DeLuca HF. Nutr Rev 66 S73-87 (2008)
  24. Binding of ligands and activation of transcription by nuclear receptors. Steinmetz AC, Renaud JP, Moras D. Annu Rev Biophys Biomol Struct 30 329-359 (2001)
  25. International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Moore DD, Kato S, Xie W, Mangelsdorf DJ, Schmidt DR, Xiao R, Kliewer SA. Pharmacol Rev 58 742-759 (2006)
  26. The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions. Slominski AT, Kim TK, Li W, Yi AK, Postlethwaite A, Tuckey RC. J Steroid Biochem Mol Biol 144 Pt A 28-39 (2014)
  27. Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands. Adorini L, Penna G, Giarratana N, Roncari A, Amuchastegui S, Daniel KC, Uskokovic M. J Steroid Biochem Mol Biol 89-90 437-441 (2004)
  28. Vitamin D: calcium and bone homeostasis during evolution. Bouillon R, Suda T. Bonekey Rep 3 480 (2014)
  29. Molecular link between vitamin D and cancer prevention. Moukayed M, Grant WB. Nutrients 5 3993-4021 (2013)
  30. Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. Reschly EJ, Krasowski MD. Curr Drug Metab 7 349-365 (2006)
  31. Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Adorini L. Int Immunopharmacol 2 1017-1028 (2002)
  32. Gastric acid, calcium absorption, and their impact on bone health. Kopic S, Geibel JP. Physiol Rev 93 189-268 (2013)
  33. Molecular action of androgens. Gobinet J, Poujol N, Sultan Ch. Mol Cell Endocrinol 198 15-24 (2002)
  34. The vitamin D receptor: contemporary genomic approaches reveal new basic and translational insights. Pike JW, Meyer MB, Lee SM, Onal M, Benkusky NA. J Clin Invest 127 1146-1154 (2017)
  35. Genetic disorders and defects in vitamin d action. Malloy PJ, Feldman D. Endocrinol Metab Clin North Am 39 333-46, table of contents (2010)
  36. The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control. Campbell FC, Xu H, El-Tanani M, Crowe P, Bingham V. Biochem Pharmacol 79 1-9 (2010)
  37. Molecular basis of the selective activity of vitamin D analogues. Carlberg C. J Cell Biochem 88 274-281 (2003)
  38. Recent advances in physiological calcium homeostasis. Ramasamy I. Clin Chem Lab Med 44 237-273 (2006)
  39. Update on biological actions of 1alpha,25(OH)2-vitamin D3 (rapid effects) and 24R,25(OH)2-vitamin D3. Norman AW, Okamura WH, Bishop JE, Henry HL. Mol Cell Endocrinol 197 1-13 (2002)
  40. Ligand-protein interactions in nuclear receptors of hormones. Egea PF, Klaholz BP, Moras D. FEBS Lett 476 62-67 (2000)
  41. Regulation of target gene expression by the vitamin D receptor - an update on mechanisms. Pike JW, Meyer MB, Bishop KA. Rev Endocr Metab Disord 13 45-55 (2012)
  42. Mutations in the vitamin D receptor and hereditary vitamin D-resistant rickets. Feldman D, J Malloy P. Bonekey Rep 3 510 (2014)
  43. Ligands for the vitamin D endocrine system: different shapes function as agonists and antagonists for genomic and rapid response receptors or as a ligand for the plasma vitamin D binding protein. Norman AW, Ishizuka S, Okamura WH. J Steroid Biochem Mol Biol 76 49-59 (2001)
  44. The role of vitamin D receptor mutations in the development of alopecia. Malloy PJ, Feldman D. Mol Cell Endocrinol 347 90-96 (2011)
  45. Digging deep into the pockets of orphan nuclear receptors: insights from structural studies. Benoit G, Malewicz M, Perlmann T. Trends Cell Biol 14 369-376 (2004)
  46. A Narrative Role of Vitamin D and Its Receptor: With Current Evidence on the Gastric Tissues. Sirajudeen S, Shah I, Al Menhali A. Int J Mol Sci 20 E3832 (2019)
  47. Different shapes of the steroid hormone 1alpha,25(OH)(2)-vitamin D(3) act as agonists for two different receptors in the vitamin D endocrine system to mediate genomic and rapid responses. Norman AW, Henry HL, Bishop JE, Song XD, Bula C, Okamura WH. Steroids 66 147-158 (2001)
  48. Structural and functional insights into nuclear receptor signaling. Jin L, Li Y. Adv Drug Deliv Rev 62 1218-1226 (2010)
  49. Mechanism of action of vitamin D and the vitamin D receptor in colorectal cancer prevention and treatment. Byers SW, Rowlands T, Beildeck M, Bong YS. Rev Endocr Metab Disord 13 31-38 (2012)
  50. Structure-function relationships of vitamin D including ligand recognition by the vitamin D receptor. Yamada S, Shimizu M, Yamamoto K. Med Res Rev 23 89-115 (2003)
  51. Vitamin D and the Liver-Correlation or Cause? Keane JT, Elangovan H, Stokes RA, Gunton JE. Nutrients 10 E496 (2018)
  52. Non-classical mechanisms of transcriptional regulation by the vitamin D receptor: insights into calcium homeostasis, immune system regulation and cancer chemoprevention. Dimitrov V, Salehi-Tabar R, An BS, White JH. J Steroid Biochem Mol Biol 144 Pt A 74-80 (2014)
  53. Functional evolution of the pregnane X receptor. Iyer M, Reschly EJ, Krasowski MD. Expert Opin Drug Metab Toxicol 2 381-397 (2006)
  54. Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. Malluche HH, Mawad H, Koszewski NJ. Kidney Int 62 367-374 (2002)
  55. Effects of vitamin D on immune disorders with special regard to asthma, COPD and autoimmune diseases: a short review. Székely JI, Pataki Á. Expert Rev Respir Med 6 683-704 (2012)
  56. Structural analysis of nuclear receptors: from isolated domains to integral proteins. Brélivet Y, Rochel N, Moras D. Mol Cell Endocrinol 348 466-473 (2012)
  57. Vitamin D receptor 2016: novel ligands and structural insights. Maestro MA, Molnár F, Mouriño A, Carlberg C. Expert Opin Ther Pat 26 1291-1306 (2016)
  58. A current structural perspective on PXR and CAR in drug metabolism. Buchman CD, Chai SC, Chen T. Expert Opin Drug Metab Toxicol 14 635-647 (2018)
  59. Vitamin D receptor ligands: the impact of crystal structures. Carlberg C, Molnár F, Mouriño A. Expert Opin Ther Pat 22 417-435 (2012)
  60. New insights on therapy with vitamin D analogs targeting the intracellular pathways that control repigmentation in human vitiligo. Birlea SA, Costin GE, Norris DA. Med Res Rev 29 514-546 (2009)
  61. The vitamin D receptor. Carlberg C, Seuter S. Dermatol Clin 25 515-23, viii (2007)
  62. Mechanisms of transcriptional repression by 1,25(OH)2 vitamin D. Kato S, Kim MS, Yamaoka K, Fujiki R. Curr Opin Nephrol Hypertens 16 297-304 (2007)
  63. Vitamin D receptor signaling and its therapeutic implications: Genome-wide and structural view. Carlberg C, Molnár F. Can J Physiol Pharmacol 93 311-318 (2015)
  64. 3D structures and ligand specificities of nuclear xenobiotic receptors CAR, PXR and VDR. Wu B, Li S, Dong D. Drug Discov Today 18 574-581 (2013)
  65. Non-genomic ecdysone effects and the invertebrate nuclear steroid hormone receptor EcR--new role for an "old" receptor? Schlattner U, Vafopoulou X, Steel CG, Hormann RE, Lezzi M. Mol Cell Endocrinol 247 64-72 (2006)
  66. Prevention of chronic allograft rejection by Vitamin D receptor agonists. Adorini L, Amuchastegui S, Daniel KC. Immunol Lett 100 34-41 (2005)
  67. Calcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic Interactions. Ben-Eltriki M, Deb S, Guns ES. J Cancer 7 391-407 (2016)
  68. Different ligands-different receptor conformations: modeling of the hER alpha LBD in complex with agonists and antagonists. Egner U, Heinrich N, Ruff M, Gangloff M, Mueller-Fahrnow A, Wurtz JM. Med Res Rev 21 523-539 (2001)
  69. The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease. Zand L, Kumar R. Endocrinol Metab Clin North Am 46 983-1007 (2017)
  70. The pleiomorphic actions of vitamin D and its importance for children. Kim SY. Ann Pediatr Endocrinol Metab 18 45-54 (2013)
  71. Structural aspects of Vitamin D endocrinology. Rochel N, Molnár F. Mol Cell Endocrinol 453 22-35 (2017)
  72. Vitamin D(3) analogs (MC 1288, KH 1060, EB 1089, GS 1558, and CB 1093): studies on their mechanism of action. Mäenpää PH, Väisänen S, Jääskeläinen T, Ryhänen S, Rouvinen J, Duchier C, Mahonen A. Steroids 66 223-225 (2001)
  73. [The vitamin D endocrine system]. Castro LC. Arq Bras Endocrinol Metabol 55 566-575 (2011)
  74. Influence of vitamin D signaling on hormone receptor status and HER2 expression in breast cancer. Zhang X, Harbeck N, Jeschke U, Doisneau-Sixou S. J Cancer Res Clin Oncol 143 1107-1122 (2017)
  75. 100 YEARS OF VITAMIN D: Historical aspects of vitamin D. Jones G. Endocr Connect 11 e210594 (2022)
  76. Insights into genetic and epigenetic determinants with impact on vitamin d signaling and cancer association studies: the case of thyroid cancer. Morand GB, Morand GB, da Silva SD, Hier MP, Alaoui-Jamali MA. Front Oncol 4 309 (2014)
  77. Vitamin D in the Context of Evolution. Carlberg C. Nutrients 14 3018 (2022)
  78. Vitamin D receptor-mediated gene regulation mechanisms and current concepts of vitamin D analog selectivity. Pike JW, Yamamoto H, Shevde NK. Adv Ren Replace Ther 9 168-174 (2002)
  79. Three-dimensional structure-function relationship of vitamin D and vitamin D receptor model. Yamada S, Yamamoto K, Masuno H, Choi M. Steroids 66 177-187 (2001)
  80. The Multiple Effects of Vitamin D against Chronic Diseases: From Reduction of Lipid Peroxidation to Updated Evidence from Clinical Studies. Berretta M, Quagliariello V, Bignucolo A, Facchini S, Maurea N, Di Francia R, Fiorica F, Sharifi S, Bressan S, Richter SN, Camozzi V, Rinaldi L, Scaroni C, Montopoli M. Antioxidants (Basel) 11 1090 (2022)
  81. Therapeutic application of vitamin D receptor ligands: an updated patent review. Takada I, Makishima M. Expert Opin Ther Pat 25 1373-1383 (2015)
  82. Beyond the human genome: examples of nuclear receptor analysis in model organisms and potential for drug discovery. Maglich JM, Sluder AE, Willson TM, Moore JT. Am J Pharmacogenomics 3 345-353 (2003)
  83. Multifunctional and potent roles of the 3-hydroxypropoxy group provide eldecalcitol's benefit in osteoporosis treatment. Ono Y. J Steroid Biochem Mol Biol 139 88-97 (2014)
  84. Relationship between Structure and Conformational Change of the Vitamin D Receptor Ligand Binding Domain in 1α,25-Dihydroxyvitamin D3 Signaling. Wan LY, Zhang YQ, Chen MD, Du YQ, Liu CB, Wu JF. Molecules 20 20473-20486 (2015)
  85. Vitamin D receptor signaling and pancreatic cancer cell EMT. Li Z, Guo J, Xie K, Zheng S. Curr Pharm Des 21 1262-1267 (2015)
  86. Inherited disorders of calcium homeostasis. Ramasamy I. Clin Chim Acta 394 22-41 (2008)
  87. Recent developments of 19-nor-1,25-dihydroxyvitamin D3 analogues. Zhang CF, Wan RZ, Liu ZP. ChemMedChem 8 1249-1260 (2013)
  88. Significance of the Vitamin D Receptor on Crosstalk with Nuclear Receptors and Regulation of Enzymes and Transporters. Noh K, Chow ECY, Quach HP, Groothuis GMM, Tirona RG, Pang KS. AAPS J 24 71 (2022)
  89. Triennial Growth Symposium--Vitamin D: bones and beyond. DeLuca HF. J Anim Sci 92 917-929 (2014)
  90. Autoimmune thyroid disease and type 1 diabetes mellitus: same pathogenesis; new perspective? Li L, Liu S, Yu J. Ther Adv Endocrinol Metab 11 2042018820958329 (2020)
  91. Structural refinement of seco-steroidal skeleton and the biological activity through nuclear receptors. Kittaka A. Yakugaku Zasshi 128 1235-1250 (2008)
  92. The Role of Vitamin D in Small Animal Bone Metabolism. Zafalon RVA, Ruberti B, Rentas MF, Amaral AR, Vendramini THA, Chacar FC, Kogika MM, Brunetto MA. Metabolites 10 E496 (2020)
  93. The development of a bone- and parathyroid-specific analog of vitamin D: 2-methylene-19-Nor-(20S)-1α,25-dihydroxyvitamin D3. Deluca HF. Bonekey Rep 3 514 (2014)
  94. Update on pharmacologically-relevant vitamin D analogues. Jones G, Kaufmann M. Br J Clin Pharmacol 85 1095-1102 (2019)
  95. Why do we need a three-dimensional architecture of the ligand-binding domain of the nuclear 1alpha,25-dihydroxyvitamin D(3) receptor? Mohr SC, Swamy N, Xu W, Ray R. Steroids 66 189-201 (2001)
  96. 19-Norvitamin D analogs for breast cancer therapy. Matsumoto Y, Kittaka A, Chen TC. Can J Physiol Pharmacol 93 333-348 (2015)
  97. Conformationally restricted mimics of vitamin D rotamers. Okamura WH, Do S, Kim H, Jeganathan S, Vu T, Zhu GD, Norman AW. Steroids 66 239-247 (2001)
  98. New Approaches to Assess Mechanisms of Action of Selective Vitamin D Analogues. Pike JW, Meyer MB. Int J Mol Sci 22 12352 (2021)
  99. Augmenting vitamin D to combat genetic disease. Peterson BR. Chem Biol 9 1265-1266 (2002)
  100. Design and Synthesis of Fluoro Analogues of Vitamin D. Kawagoe F, Mototani S, Kittaka A. Int J Mol Sci 22 8191 (2021)
  101. Ring-A-seco analogs of 1α,25-dihydroxy-19-norvitamin D3. Glebocka A, Sicinski RR, Plum LA, Deluca HF. J Steroid Biochem Mol Biol 136 39-43 (2013)
  102. The Synthesis and Biological Evaluation of D-Ring-Modified Vitamin D Analogues. Kawagoe F, Mototani S, Kittaka A. Biomolecules 11 1639 (2021)
  103. [Analysis of molecular mechanism of cancer cell differentiation and apoptosis induced by vitamin D3 analogs on the basis of molecular recognition of vitamin D receptor ligand binding domain]. Nakagawa K. Yakugaku Zasshi 122 781-791 (2002)
  104. Androgens and Their Role in Regulating Sex Differences in the Hypothalamic/Pituitary/Adrenal Axis Stress Response and Stress-Related Behaviors. Sheng JA, Tan SML, Hale TM, Handa RJ. Androg Clin Res Ther 2 261-274 (2021)
  105. Discovery of Nuclear Receptor Ligands and Elucidation of Their Mechanisms of Action. Yamamoto K. Chem Pharm Bull (Tokyo) 67 609-619 (2019)
  106. Influence of Vitamin D on Periodontal Inflammation: A Review. Meghil MM, Cutler CW. Pathogens 12 1180 (2023)
  107. Synthesis of novel C-2 substituted vitamin D derivatives having ringed side chains and their biological evaluation on bone. Saito H, Takagi K, Horie K, Kakuda S, Takimoto-Kamimura M, Ochiai E, Chida T, Harada Y, Takenouchi K, Kittaka A. J Steroid Biochem Mol Biol 136 3-8 (2013)
  108. Vitamin D3 Metabolism and Its Role in Temporomandibular Joint Osteoarthritis and Autoimmune Thyroid Diseases. Szulc M, Świątkowska-Stodulska R, Pawłowska E, Derwich M. Int J Mol Sci 24 4080 (2023)
  109. Adjudication of the alleged role of vitamin d in the antimicrobial pathway. Higa GM, Hicks J, Isabella C. Scientifica (Cairo) 2012 129516 (2012)
  110. Calcifediol: Mechanisms of Action. Donati S, Palmini G, Aurilia C, Falsetti I, Marini F, Giusti F, Iantomasi T, Brandi ML. Nutrients 15 4409 (2023)
  111. Full-length nuclear receptor allosteric regulation. Choi WJ, Haratipour Z, Blind RD. J Lipid Res 64 100406 (2023)
  112. [Creation of functional organic compounds and their applications]. Takayama H. Yakugaku Zasshi 122 127-155 (2002)

Articles citing this publication (239)

  1. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A, Bäsler S, Schäfer M, Egner U, Carrondo MA. J Biol Chem 275 26164-26171 (2000)
  2. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, Haussler CA, Galligan MA, Thatcher ML, Encinas Dominguez C, Haussler MR. Mol Cell Endocrinol 177 145-159 (2001)
  3. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. Wang TT, Dabbas B, Laperriere D, Bitton AJ, Soualhine H, Tavera-Mendoza LE, Dionne S, Servant MJ, Bitton A, Seidman EG, Mader S, Behr MA, White JH. J Biol Chem 285 2227-2231 (2010)
  4. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y, Wu GY, Scheffler JE, Salvati ME, Krystek SR, Weinmann R, Einspahr HM. Proc Natl Acad Sci U S A 98 4904-4909 (2001)
  5. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Downes M, Verdecia MA, Roecker AJ, Hughes R, Hogenesch JB, Kast-Woelbern HR, Bowman ME, Ferrer JL, Anisfeld AM, Edwards PA, Rosenfeld JM, Alvarez JG, Noel JP, Nicolaou KC, Evans RM. Mol Cell 11 1079-1092 (2003)
  6. Crystal structure of the human RXRalpha ligand-binding domain bound to its natural ligand: 9-cis retinoic acid. Egea PF, Mitschler A, Rochel N, Ruff M, Chambon P, Moras D. EMBO J 19 2592-2601 (2000)
  7. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Shah S, Islam MN, Dakshanamurthy S, Rizvi I, Rao M, Herrell R, Zinser G, Valrance M, Aranda A, Moras D, Norman A, Welsh J, Byers SW. Mol Cell 21 799-809 (2006)
  8. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mi LZ, Devarakonda S, Harp JM, Han Q, Pellicciari R, Willson TM, Khorasanizadeh S, Rastinejad F. Mol Cell 11 1093-1100 (2003)
  9. Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. Watkins RE, Davis-Searles PR, Lambert MH, Redinbo MR. J Mol Biol 331 815-828 (2003)
  10. A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer. Xu RX, Lambert MH, Wisely BB, Warren EN, Weinert EE, Waitt GM, Williams JD, Collins JL, Moore LB, Willson TM, Moore JT. Mol Cell 16 919-928 (2004)
  11. Structural adaptability in the ligand-binding pocket of the ecdysone hormone receptor. Billas IM, Iwema T, Garnier JM, Mitschler A, Rochel N, Moras D. Nature 426 91-96 (2003)
  12. The nuclear xenobiotic receptor CAR: structural determinants of constitutive activation and heterodimerization. Suino K, Peng L, Reynolds R, Li Y, Cha JY, Repa JJ, Kliewer SA, Xu HE. Mol Cell 16 893-905 (2004)
  13. Physical and functional interaction between the vitamin D receptor and hairless corepressor, two proteins required for hair cycling. Hsieh JC, Sisk JM, Jurutka PW, Haussler CA, Slater SA, Haussler MR, Thompson CC. J Biol Chem 278 38665-38674 (2003)
  14. DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex. Zhang J, Chalmers MJ, Stayrook KR, Burris LL, Wang Y, Busby SA, Pascal BD, Garcia-Ordonez RD, Bruning JB, Istrate MA, Kojetin DJ, Dodge JA, Burris TP, Griffin PR. Nat Struct Mol Biol 18 556-563 (2011)
  15. Common architecture of nuclear receptor heterodimers on DNA direct repeat elements with different spacings. Rochel N, Ciesielski F, Godet J, Moman E, Roessle M, Peluso-Iltis C, Moulin M, Haertlein M, Callow P, Mély Y, Svergun DI, Moras D. Nat Struct Mol Biol 18 564-570 (2011)
  16. The role of androgen receptor mutations in prostate cancer progression. Brooke GN, Bevan CL. Curr Genomics 10 18-25 (2009)
  17. Transcription activation by the ecdysone receptor (EcR/USP): identification of activation functions. Hu X, Cherbas L, Cherbas P. Mol Endocrinol 17 716-731 (2003)
  18. 1,25-Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis. Mayne CG, Spanier JA, Relland LM, Williams CB, Hayes CE. Eur J Immunol 41 822-832 (2011)
  19. Spatio-temporal activation of chromatin on the human CYP24 gene promoter in the presence of 1alpha,25-Dihydroxyvitamin D3. Väisänen S, Dunlop TW, Sinkkonen L, Frank C, Carlberg C. J Mol Biol 350 65-77 (2005)
  20. Structural basis of digoxin that antagonizes RORgamma t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production. Fujita-Sato S, Ito S, Isobe T, Ohyama T, Wakabayashi K, Morishita K, Ando O, Isono F. J Biol Chem 286 31409-31417 (2011)
  21. Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Steketee K, Timmerman L, Ziel-van der Made AC, Doesburg P, Brinkmann AO, Trapman J. Int J Cancer 100 309-317 (2002)
  22. X-ray structure of the orphan nuclear receptor RORbeta ligand-binding domain in the active conformation. Stehlin C, Wurtz JM, Steinmetz A, Greiner E, Schüle R, Moras D, Renaud JP. EMBO J 20 5822-5831 (2001)
  23. 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. Lou YR, Molnár F, Peräkylä M, Qiao S, Kalueff AV, St-Arnaud R, Carlberg C, Tuohimaa P. J Steroid Biochem Mol Biol 118 162-170 (2010)
  24. Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. Adachi R, Honma Y, Masuno H, Kawana K, Shimomura I, Yamada S, Makishima M. J Lipid Res 46 46-57 (2005)
  25. Structure of the murine constitutive androstane receptor complexed to androstenol: a molecular basis for inverse agonism. Shan L, Vincent J, Brunzelle JS, Dussault I, Lin M, Ianculescu I, Sherman MA, Forman BM, Fernandez EJ. Mol Cell 16 907-917 (2004)
  26. Analysis of protein dimerization and ligand binding of orphan receptor HNF4alpha. Bogan AA, Dallas-Yang Q, Ruse MD, Maeda Y, Jiang G, Nepomuceno L, Scanlan TS, Cohen FE, Sladek FM. J Mol Biol 302 831-851 (2000)
  27. Structural basis of VDR-DNA interactions on direct repeat response elements. Shaffer PL, Gewirth DT. EMBO J 21 2242-2252 (2002)
  28. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Thompson PD, Jurutka PW, Whitfield GK, Myskowski SM, Eichhorst KR, Dominguez CE, Haussler CA, Haussler MR. Biochem Biophys Res Commun 299 730-738 (2002)
  29. Structural analysis of CYP2R1 in complex with vitamin D3. Strushkevich N, Usanov SA, Plotnikov AN, Jones G, Park HW. J Mol Biol 380 95-106 (2008)
  30. Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Krasowski MD, Ni A, Hagey LR, Ekins S. Mol Cell Endocrinol 334 39-48 (2011)
  31. Functional evolution of the vitamin D and pregnane X receptors. Reschly EJ, Bainy AC, Mattos JJ, Hagey LR, Bahary N, Mada SR, Ou J, Venkataramanan R, Krasowski MD. BMC Evol Biol 7 222 (2007)
  32. Cloning of a functional vitamin D receptor from the lamprey (Petromyzon marinus), an ancient vertebrate lacking a calcified skeleton and teeth. Whitfield GK, Dang HT, Schluter SF, Bernstein RM, Bunag T, Manzon LA, Hsieh G, Dominguez CE, Youson JH, Haussler MR, Marchalonis JJ. Endocrinology 144 2704-2716 (2003)
  33. Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding. Pissios P, Tzameli I, Kushner P, Moore DD. Mol Cell 6 245-253 (2000)
  34. Effects of ligand binding on the association properties and conformation in solution of retinoic acid receptors RXR and RAR. Egea PF, Rochel N, Birck C, Vachette P, Timmins PA, Moras D. J Mol Biol 307 557-576 (2001)
  35. Molecular and functional comparison of 1,25-dihydroxyvitamin D(3) and the novel vitamin D receptor ligand, lithocholic acid, in activating transcription of cytochrome P450 3A4. Jurutka PW, Thompson PD, Whitfield GK, Eichhorst KR, Hall N, Dominguez CE, Hsieh JC, Haussler CA, Haussler MR. J Cell Biochem 94 917-943 (2005)
  36. Evolution of pharmacologic specificity in the pregnane X receptor. Ekins S, Reschly EJ, Hagey LR, Krasowski MD. BMC Evol Biol 8 103 (2008)
  37. 2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. Yamamoto H, Shevde NK, Warrier A, Plum LA, DeLuca HF, Pike JW. J Biol Chem 278 31756-31765 (2003)
  38. Vitamin D: Newer Concepts of Its Metabolism and Function at the Basic and Clinical Level. Bikle DD. J Endocr Soc 4 bvz038 (2020)
  39. Nuclear import of the retinoid X receptor, the vitamin D receptor, and their mutual heterodimer. Yasmin R, Williams RM, Xu M, Noy N. J Biol Chem 280 40152-40160 (2005)
  40. Distinct conformational states of nuclear receptor-bound CRSP-Med complexes. Taatjes DJ, Schneider-Poetsch T, Tjian R. Nat Struct Mol Biol 11 664-671 (2004)
  41. Identification and characterization of 1,25D3-membrane-associated rapid response, steroid (1,25D3-MARRS) binding protein. Nemere I, Safford SE, Rohe B, DeSouza MM, Farach-Carson MC. J Steroid Biochem Mol Biol 89-90 281-285 (2004)
  42. The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D3. Pike JW, Meyer MB. Rheum Dis Clin North Am 38 13-27 (2012)
  43. Evolutionary selection across the nuclear hormone receptor superfamily with a focus on the NR1I subfamily (vitamin D, pregnane X, and constitutive androstane receptors). Krasowski MD, Yasuda K, Hagey LR, Schuetz EG. Nucl Recept 3 2 (2005)
  44. Enhancement of VDR-mediated transcription by phosphorylation: correlation with increased interaction between the VDR and DRIP205, a subunit of the VDR-interacting protein coactivator complex. Barletta F, Freedman LP, Christakos S. Mol Endocrinol 16 301-314 (2002)
  45. Structure and function of CRSP/Med2; a promoter-selective transcriptional coactivator complex. Taatjes DJ, Tjian R. Mol Cell 14 675-683 (2004)
  46. Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators. Molnár F, Matilainen M, Carlberg C. J Biol Chem 280 26543-26556 (2005)
  47. 1α,25(OH)2-3-epi-vitamin D3, a natural physiological metabolite of vitamin D3: its synthesis, biological activity and crystal structure with its receptor. Molnár F, Sigüeiro R, Sato Y, Araujo C, Schuster I, Antony P, Peluso J, Muller C, Mouriño A, Moras D, Rochel N. PLoS One 6 e18124 (2011)
  48. Alternative splicing within the ligand binding domain of the human constitutive androstane receptor. Savkur RS, Wu Y, Bramlett KS, Wang M, Yao S, Perkins D, Totten M, Searfoss G, Ryan TP, Su EW, Burris TP. Mol Genet Metab 80 216-226 (2003)
  49. Human PXR forms a tryptophan zipper-mediated homodimer. Noble SM, Carnahan VE, Moore LB, Luntz T, Wang H, Ittoop OR, Stimmel JB, Davis-Searles PR, Watkins RE, Wisely GB, LeCluyse E, Tripathy A, McDonnell DP, Redinbo MR. Biochemistry 45 8579-8589 (2006)
  50. Structural determinants for vitamin D receptor response to endocrine and xenobiotic signals. Adachi R, Shulman AI, Yamamoto K, Shimomura I, Yamada S, Mangelsdorf DJ, Makishima M. Mol Endocrinol 18 43-52 (2004)
  51. Adaptability of the Vitamin D nuclear receptor to the synthetic ligand Gemini: remodelling the LBP with one side chain rotation. Ciesielski F, Rochel N, Moras D. J Steroid Biochem Mol Biol 103 235-242 (2007)
  52. The retinoid-X receptor ortholog, ultraspiracle, binds with nanomolar affinity to an endogenous morphogenetic ligand. Jones G, Jones D, Teal P, Sapa A, Wozniak M. FEBS J 273 4983-4996 (2006)
  53. Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines. Beildeck ME, Islam M, Shah S, Welsh J, Byers SW. PLoS One 4 e7872 (2009)
  54. Intrinsic disorder in nuclear hormone receptors. Krasowski MD, Reschly EJ, Ekins S. J Proteome Res 7 4359-4372 (2008)
  55. Quantification of the vitamin D receptor-coregulator interaction. Teichert A, Arnold LA, Otieno S, Oda Y, Augustinaite I, Geistlinger TR, Kriwacki RW, Guy RK, Bikle DD. Biochemistry 48 1454-1461 (2009)
  56. Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction. Eelen G, Verlinden L, Rochel N, Claessens F, De Clercq P, Vandewalle M, Tocchini-Valentini G, Moras D, Bouillon R, Verstuyf A. Mol Pharmacol 67 1566-1573 (2005)
  57. Amino acids important for ligand specificity of the human constitutive androstane receptor. Jyrkkärinne J, Windshügel B, Mäkinen J, Ylisirniö M, Peräkylä M, Poso A, Sippl W, Honkakoski P. J Biol Chem 280 5960-5971 (2005)
  58. A new model for 20-hydroxyecdysone and dibenzoylhydrazine binding: a homology modeling and docking approach. Wurtz JM, Guillot B, Fagart J, Moras D, Tietjen K, Schindler M. Protein Sci 9 1073-1084 (2000)
  59. Vitamin D metabolism and effects on pluripotency genes and cell differentiation in testicular germ cell tumors in vitro and in vivo. Blomberg Jensen M, Jørgensen A, Nielsen JE, Steinmeyer A, Leffers H, Juul A, Rajpert-De Meyts E. Neoplasia 14 952-963 (2012)
  60. Critical role of helix 12 of the vitamin D(3) receptor for the partial agonism of carboxylic ester antagonists. Väisänen S, Peräkylä M, Kärkkäinen JI, Steinmeyer A, Carlberg C. J Mol Biol 315 229-238 (2002)
  61. Vitamin D receptor agonists specifically modulate the volume of the ligand-binding pocket. Molnár F, Peräkylä M, Carlberg C. J Biol Chem 281 10516-10526 (2006)
  62. Functional and structural characterization of the insertion region in the ligand binding domain of the vitamin D nuclear receptor. Rochel N, Tocchini-Valentini G, Egea PF, Juntunen K, Garnier JM, Vihko P, Moras D. Eur J Biochem 268 971-979 (2001)
  63. Identification of residues in the PXR ligand binding domain critical for species specific and constitutive activation. Ostberg T, Bertilsson G, Jendeberg L, Berkenstam A, Uppenberg J. Eur J Biochem 269 4896-4904 (2002)
  64. Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist. Tavera-Mendoza LE, Quach TD, Dabbas B, Hudon J, Liao X, Palijan A, Gleason JL, White JH. Proc Natl Acad Sci U S A 105 8250-8255 (2008)
  65. Stabilization of androgen receptor protein is induced by agonist, not by antagonists. Furutani T, Watanabe T, Tanimoto K, Hashimoto T, Koutoku H, Kudoh M, Shimizu Y, Kato S, Shikama H. Biochem Biophys Res Commun 294 779-784 (2002)
  66. Colon cancer and solar ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its Gemini analogs. Spina C, Tangpricha V, Yao M, Zhou W, Wolfe MM, Maehr H, Uskokovic M, Adorini L, Holick MF. J Steroid Biochem Mol Biol 97 111-120 (2005)
  67. Metabolism of A-ring diastereomers of 1alpha,25-dihydroxyvitamin D3 by CYP24A1. Kusudo T, Sakaki T, Abe D, Fujishima T, Kittaka A, Takayama H, Hatakeyama S, Ohta M, Inouye K. Biochem Biophys Res Commun 321 774-782 (2004)
  68. Stop codon readthrough generates a C-terminally extended variant of the human vitamin D receptor with reduced calcitriol response. Loughran G, Jungreis I, Tzani I, Power M, Dmitriev RI, Ivanov IP, Kellis M, Atkins JF. J Biol Chem 293 4434-4444 (2018)
  69. Vitamin D-resistant rickets and type 1 diabetes in a child with compound heterozygous mutations of the vitamin D receptor (L263R and R391S): dissociated responses of the CYP-24 and rel-B promoters to 1,25-dihydroxyvitamin D3. Nguyen M, d'Alesio A, Pascussi JM, Kumar R, Griffin MD, Dong X, Guillozo H, Rizk-Rabin M, Sinding C, Bougnères P, Jehan F, Garabédian M. J Bone Miner Res 21 886-894 (2006)
  70. Vitamin D3 derivatives with adamantane or lactone ring side chains are cell type-selective vitamin D receptor modulators. Inaba Y, Yamamoto K, Yoshimoto N, Matsunawa M, Uno S, Yamada S, Makishima M. Mol Pharmacol 71 1298-1311 (2007)
  71. A novel inborn error in the ligand-binding domain of the vitamin D receptor causes hereditary vitamin D-resistant rickets. Malloy PJ, Zhu W, Zhao XY, Pehling GB, Feldman D. Mol Genet Metab 73 138-148 (2001)
  72. Involvement of SMRT corepressor in transcriptional repression by the vitamin D receptor. Kim JY, Son YL, Lee YC. Mol Endocrinol 23 251-264 (2009)
  73. A vitamin D receptor selectively activated by gemini analogs reveals ligand dependent and independent effects. Huet T, Laverny G, Ciesielski F, Molnár F, Ramamoorthy TG, Belorusova AY, Antony P, Potier N, Metzger D, Moras D, Rochel N. Cell Rep 10 516-526 (2015)
  74. Crustacean retinoid-X receptor isoforms: distinctive DNA binding and receptor-receptor interaction with a cognate ecdysteroid receptor. Wu X, Hopkins PM, Palli SR, Durica DS. Mol Cell Endocrinol 218 21-38 (2004)
  75. Interaction between vitamin D receptor and vitamin D ligands: two-dimensional alanine scanning mutational analysis. Choi M, Yamamoto K, Itoh T, Makishima M, Mangelsdorf DJ, Moras D, DeLuca HF, Yamada S. Chem Biol 10 261-270 (2003)
  76. Vitamin D analogue-specific recruitment of vitamin D receptor coactivators. Issa LL, Leong GM, Sutherland RL, Eisman JA. J Bone Miner Res 17 879-890 (2002)
  77. Vitamin D receptor mutations in patients with hereditary 1,25-dihydroxyvitamin D-resistant rickets. Malloy PJ, Tasic V, Taha D, Tütüncüler F, Ying GS, Yin LK, Wang J, Feldman D. Mol Genet Metab 111 33-40 (2014)
  78. Ligand unbinding pathways from the vitamin D receptor studied by molecular dynamics simulations. Peräkylä M. Eur Biophys J 38 185-198 (2009)
  79. Agonist-triggered modulation of the activated and silent state of the vitamin D(3) receptor by interaction with co-repressors and co-activators. Herdick M, Carlberg C. J Mol Biol 304 793-801 (2000)
  80. Crystal structures of complexes of vitamin D receptor ligand-binding domain with lithocholic acid derivatives. Masuno H, Ikura T, Morizono D, Orita I, Yamada S, Shimizu M, Ito N. J Lipid Res 54 2206-2213 (2013)
  81. Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA. J Med Chem 55 4640-4651 (2012)
  82. Evidence for 1,25-dihydroxyvitamin D3-independent transactivation by the vitamin D receptor: uncoupling the receptor and ligand in keratinocytes. Ellison TI, Eckert RL, MacDonald PN. J Biol Chem 282 10953-10962 (2007)
  83. Synthesis of 1alpha,25-dihydroxyvitamin D3-26,23-lactams (DLAMs), a novel series of 1 alpha,25-dihydroxyvitamin D3 antagonist. Kato Y, Nakano Y, Sano H, Tanatani A, Kobayashi H, Shimazawa R, Koshino H, Hashimoto Y, Nagasawa K. Bioorg Med Chem Lett 14 2579-2583 (2004)
  84. A unique insertion/duplication in the VDR gene that truncates the VDR causing hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. Malloy PJ, Wang J, Peng L, Nayak S, Sisk JM, Thompson CC, Feldman D. Arch Biochem Biophys 460 285-292 (2007)
  85. Ligands with a 3,3-diphenylpentane skeleton for nuclear vitamin D and androgen receptors: Dual activities and metabolic activation. Hosoda S, Tanatani A, Wakabayashi K, Makishima M, Imai K, Miyachi H, Nagasawa K, Hashimoto Y. Bioorg Med Chem 14 5489-5502 (2006)
  86. Method for comparing the structures of protein ligand-binding sites and application for predicting protein-drug interactions. Minai R, Matsuo Y, Onuki H, Hirota H. Proteins 72 367-381 (2008)
  87. Ligand recognition by the vitamin D receptor. Choi M, Yamamoto K, Masuno H, Nakashima K, Taga T, Yamada S. Bioorg Med Chem 9 1721-1730 (2001)
  88. Side-chain modified vitamin D analogs induce rapid accumulation of VDR in the cell nuclei proportionately to their differentiation-inducing potential. Gocek E, Kiełbiński M, Wyłób P, Kutner A, Marcinkowska E. Steroids 73 1359-1366 (2008)
  89. The critical role of carboxy-terminal amino acids in ligand-dependent and -independent transactivation of the constitutive androstane receptor. Andersin T, Väisänen S, Carlberg C. Mol Endocrinol 17 234-246 (2003)
  90. Vitamin D receptor modulates the neoplastic phenotype through antagonistic growth regulatory signals. Xu H, McCann M, Zhang Z, Posner GH, Bingham V, El-Tanani M, Campbell FC. Mol Carcinog 48 758-772 (2009)
  91. Antagonist- and inverse agonist-driven interactions of the vitamin D receptor and the constitutive androstane receptor with corepressor protein. Lempiäinen H, Molnár F, Macias Gonzalez M, Peräkylä M, Carlberg C. Mol Endocrinol 19 2258-2272 (2005)
  92. Structural conservation of ligand binding reveals a bile acid-like signaling pathway in nematodes. Zhi X, Zhou XE, Melcher K, Motola DL, Gelmedin V, Hawdon J, Kliewer SA, Mangelsdorf DJ, Xu HE. J Biol Chem 287 4894-4903 (2012)
  93. Tryptophan missense mutation in the ligand-binding domain of the vitamin D receptor causes severe resistance to 1,25-dihydroxyvitamin D. Nguyen TM, Adiceam P, Kottler ML, Guillozo H, Rizk-Rabin M, Brouillard F, Lagier P, Palix C, Garnier JM, Garabedian M. J Bone Miner Res 17 1728-1737 (2002)
  94. A unique insertion/substitution in helix H1 of the vitamin D receptor ligand binding domain in a patient with hereditary 1,25-dihydroxyvitamin D-resistant rickets. Malloy PJ, Xu R, Cattani A, Reyes mL, Feldman D. J Bone Miner Res 19 1018-1024 (2004)
  95. Controlling the chromatin organization of vitamin D target genes by multiple vitamin D receptor binding sites. Carlberg C, Dunlop TW, Saramäki A, Sinkkonen L, Matilainen M, Väisänen S. J Steroid Biochem Mol Biol 103 338-343 (2007)
  96. Evolution of the interaction between Runx2 and VDR, two transcription factors involved in osteoblastogenesis. Marcellini S, Bruna C, Henríquez JP, Albistur M, Reyes AE, Barriga EH, Henríquez B, Montecino M. BMC Evol Biol 10 78 (2010)
  97. Hereditary vitamin D resistant rickets: identification of a novel splice site mutation in the vitamin D receptor gene and successful treatment with oral calcium therapy. Ma NS, Malloy PJ, Pitukcheewanont P, Dreimane D, Geffner ME, Feldman D. Bone 45 743-746 (2009)
  98. Hereditary vitamin D-resistant rickets (HVDRR) owing to a heterozygous mutation in the vitamin D receptor. Malloy PJ, Zhou Y, Wang J, Hiort O, Feldman D. J Bone Miner Res 26 2710-2718 (2011)
  99. Identification of a highly potent vitamin D receptor antagonist: (25S)-26-adamantyl-25-hydroxy-2-methylene-22,23-didehydro-19,27-dinor-20-epi-vitamin D3 (ADMI3). Igarashi M, Yoshimoto N, Yamamoto K, Shimizu M, Ishizawa M, Makishima M, DeLuca HF, Yamada S. Arch Biochem Biophys 460 240-253 (2007)
  100. Molecular evaluation of vitamin D3 receptor agonists designed for topical treatment of skin diseases. Bury Y, Ruf D, Hansen CM, Kissmeyer AM, Binderup L, Carlberg C. J Invest Dermatol 116 785-792 (2001)
  101. Structural evaluation of the agonistic action of a vitamin D analog with two side chains binding to the nuclear vitamin D receptor. Väisänen S, Peräkylä M, Kärkkäinen JI, Uskokovic MR, Carlberg C. Mol Pharmacol 63 1230-1237 (2003)
  102. Structure-based design of a superagonist ligand for the vitamin D nuclear receptor. Hourai S, Rodrigues LC, Antony P, Reina-San-Martin B, Ciesielski F, Magnier BC, Schoonjans K, Mouriño A, Rochel N, Moras D. Chem Biol 15 383-392 (2008)
  103. Superagonistic fluorinated vitamin D3 analogs stabilize helix 12 of the vitamin D receptor. Eelen G, Valle N, Sato Y, Rochel N, Verlinden L, De Clercq P, Moras D, Bouillon R, Muñoz A, Verstuyf A. Chem Biol 15 1029-1034 (2008)
  104. Peroxisome proliferation-activated receptor δ agonist GW0742 interacts weakly with multiple nuclear receptors, including the vitamin D receptor. Nandhikonda P, Yasgar A, Baranowski AM, Sidhu PS, McCallum MM, Pawlak AJ, Teske K, Feleke B, Yuan NY, Kevin C, Bikle DD, Ayers SD, Webb P, Rai G, Simeonov A, Jadhav A, Maloney D, Arnold LA. Biochemistry 52 4193-4203 (2013)
  105. A novel mutation in the VDR gene in hereditary vitamin D-resistant rickets. Arita K, Nanda A, Wessagowit V, Akiyama M, Alsaleh QA, McGrath JA. Br J Dermatol 158 168-171 (2008)
  106. Molecular mechanism of the vitamin D antagonistic actions of (23S)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone depends on the primary structure of the carboxyl-terminal region of the vitamin d receptor. Ochiai E, Miura D, Eguchi H, Ohara S, Takenouchi K, Azuma Y, Kamimura T, Norman AW, Ishizuka S. Mol Endocrinol 19 1147-1157 (2005)
  107. Thyroid hormone receptor mutations in cancer and resistance to thyroid hormone: perspective and prognosis. Rosen MD, Privalsky ML. J Thyroid Res 2011 361304 (2011)
  108. 2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation, and crystal structure. Shimizu M, Miyamoto Y, Takaku H, Matsuo M, Nakabayashi M, Masuno H, Udagawa N, DeLuca HF, Ikura T, Ito N. Bioorg Med Chem 16 6949-6964 (2008)
  109. Effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: A systematic review and meta-analysis. Li XH, Feng L, Yang ZH, Liao YH. Nephrology (Carlton) 20 706-714 (2015)
  110. Glucocorticoid receptor-interacting protein-1 and receptor-associated coactivator-3 differentially interact with the vitamin D receptor (VDR) and regulate VDR-retinoid X receptor transcriptional cross-talk. Issa LL, Leong GM, Barry JB, Sutherland RL, Eisman JA. Endocrinology 142 1606-1615 (2001)
  111. Structurally and functionally important amino acids of the agonistic conformation of the human vitamin D receptor. Väisänen S, Ryhänen S, Saarela JT, Peräkylä M, Andersin T, Mäenpää PH. Mol Pharmacol 62 788-794 (2002)
  112. Automating human intuition for protein design. Nivón LG, Bjelic S, King C, Baker D. Proteins 82 858-866 (2014)
  113. Compound heterozygous mutations in the vitamin D receptor in a patient with hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia. Zhou Y, Wang J, Malloy PJ, Dolezel Z, Feldman D. J Bone Miner Res 24 643-651 (2009)
  114. Ligand-mediated conformational changes of the VDR are required for gene transactivation. Carlberg C. J Steroid Biochem Mol Biol 89-90 227-232 (2004)
  115. Structural investigation of the ligand binding domain of the zebrafish VDR in complexes with 1alpha,25(OH)2D3 and Gemini: purification, crystallization and preliminary X-ray diffraction analysis. Ciesielski F, Rochel N, Mitschler A, Kouzmenko A, Moras D. J Steroid Biochem Mol Biol 89-90 55-59 (2004)
  116. A structural basis for the species-specific antagonism of 26,23-lactones on vitamin D signaling. Peräkylä M, Molnár F, Carlberg C. Chem Biol 11 1147-1156 (2004)
  117. Antifibrotic vitamin D analogs. Bonventre JV. J Clin Invest 123 4570-4573 (2013)
  118. Crystal structure of the vitamin D nuclear receptor ligand binding domain in complex with a locked side chain analog of calcitriol. Rochel N, Hourai S, Pérez-García X, Rumbo A, Mourino A, Moras D. Arch Biochem Biophys 460 172-176 (2007)
  119. Design and synthesis of potent vitamin D receptor antagonists with A-ring modifications: remarkable effects of 2alpha-methyl introduction on antagonistic activity. Fujishima T, Kojima Y, Azumaya I, Kittaka A, Takayama H. Bioorg Med Chem 11 3621-3631 (2003)
  120. Highly potent cell differentiation-inducing analogues of 1alpha,25-dihydroxyvitamin D3: synthesis and biological activity of 2-methyl-1,25-dihydroxyvitamin D3 with side-chain modifications. Fujishima T, Zhaopeng L, Konno K, Nakagawa K, Okano T, Yamaguchi K, Takayama H. Bioorg Med Chem 9 525-535 (2001)
  121. On the mechanism underlying (23S)-25-dehydro-1alpha(OH)-vitamin D3-26,23-lactone antagonism of hVDRwt gene activation and its switch to a superagonist. Mizwicki MT, Bula CM, Mahinthichaichan P, Henry HL, Ishizuka S, Norman AW. J Biol Chem 284 36292-36301 (2009)
  122. Selective regulation of gene expression by an orthogonal estrogen receptor-ligand pair created by polar-group exchange. Shi Y, Koh JT. Chem Biol 8 501-510 (2001)
  123. Structure-function study of gemini derivatives with two different side chains at C-20, Gemini-0072 and Gemini-0097. Huet T, Maehr H, Lee HJ, Uskokovic MR, Suh N, Moras D, Rochel N. Medchemcomm 2 424-429 (2011)
  124. 1alpha,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells. Swamy N, Persons KS, Chen TC, Ray R. J Cell Biochem 89 909-916 (2003)
  125. 2-Methylene 19-nor-25-dehydro-1alpha-hydroxyvitamin D3 26,23-lactones: synthesis, biological activities and molecular basis of passive antagonism. Yoshimoto N, Inaba Y, Yamada S, Makishima M, Shimizu M, Yamamoto K. Bioorg Med Chem 16 457-473 (2008)
  126. A functionally orthogonal ligand-receptor pair created by targeting the allosteric mechanism of the thyroid hormone receptor. Hassan AQ, Koh JT. J Am Chem Soc 128 8868-8874 (2006)
  127. A perspective on how the Vitamin D sterol/Vitamin D receptor (VDR) conformational ensemble model can potentially be used to understand the structure-function results of A-ring modified Vitamin D sterols. Mizwicki MT, Bula CM, Bishop JE, Norman AW. J Steroid Biochem Mol Biol 97 69-82 (2005)
  128. An expeditious route to 1alpha,25-dihydroxyvitamin D(3) and its analogues by an aqueous tandem palladium-catalyzed a-ring closure and suzuki coupling to the C/D unit. Gogoi P, Sigüeiro R, Eduardo S, Mouriño A. Chemistry 16 1432-1435 (2010)
  129. Functional diversification of vitamin D receptor paralogs in teleost fish after a whole genome duplication event. Kollitz EM, Hawkins MB, Whitfield GK, Kullman SW. Endocrinology 155 4641-4654 (2014)
  130. Highly potent vitamin D receptor antagonists: design, synthesis, and biological evaluation. Saito N, Kittaka A. Chembiochem 7 1479-1490 (2006)
  131. Novel synthesis of 2-substituted 19-norvitamin D A-ring phosphine oxide from D-glucose as a building block. Shimizu M, Iwasaki Y, Shibamoto Y, Sato M, DeLuca HF, Yamada S. Bioorg Med Chem Lett 13 809-812 (2003)
  132. Biological activities of 2alpha-substituted analogues of 1alpha,25-dihydroxyvitamin D3 in transcriptional regulation and human promyelocytic leukemia (HL-60) cell proliferation and differentiation. Takahashi E, Nakagawa K, Suhara Y, Kittaka A, Nihei K, Konno K, Takayama H, Ozono K, Okano T. Biol Pharm Bull 29 2246-2250 (2006)
  133. Comparison of homology models and X-ray structures of the nuclear receptor CAR: assessing the structural basis of constitutive activity. Windshügel B, Jyrkkärinne J, Vanamo J, Poso A, Honkakoski P, Sippl W. J Mol Graph Model 25 644-657 (2007)
  134. DDX5 is a multifunctional co-activator of steroid hormone receptors. Wagner M, Rid R, Maier CJ, Maier RH, Laimer M, Hintner H, Bauer JW, Onder K. Mol Cell Endocrinol 361 80-91 (2012)
  135. Folding and stability of the ligand-binding domain of the glucocorticoid receptor. McLaughlin SH, Jackson SE. Protein Sci 11 1926-1936 (2002)
  136. HDX reveals unique fragment ligands for the vitamin D receptor. Carson MW, Zhang J, Chalmers MJ, Bocchinfuso WP, Holifield KD, Masquelin T, Stites RE, Stayrook KR, Griffin PR, Dodge JA. Bioorg Med Chem Lett 24 3459-3463 (2014)
  137. Molecular determinants of MED1 interaction with the DNA bound VDR-RXR heterodimer. Belorusova AY, Bourguet M, Hessmann S, Chalhoub S, Kieffer B, Cianférani S, Rochel N. Nucleic Acids Res 48 11199-11213 (2020)
  138. Molecular dynamics simulations of the human CAR ligand-binding domain: deciphering the molecular basis for constitutive activity. Windshügel B, Jyrkkärinne J, Poso A, Honkakoski P, Sippl W. J Mol Model 11 69-79 (2005)
  139. New derivatives of 1alpha,25-dihydroxy-19-norvitamin D3 with two substituents at C-2: synthesis and biological activity. Shimizu M, Iwasaki Y, Shimazaki M, Amano Y, Yamamoto K, Reischl W, Yamada S. Bioorg Med Chem Lett 15 1451-1455 (2005)
  140. Structural basis for vitamin D receptor agonism by novel non-secosteroidal ligands. Asano L, Ito I, Kuwabara N, Waku T, Yanagisawa J, Miyachi H, Shimizu T. FEBS Lett 587 957-963 (2013)
  141. Structural basis of the histidine-mediated vitamin D receptor agonistic and antagonistic mechanisms of (23S)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone. Kakuda S, Ishizuka S, Eguchi H, Mizwicki MT, Norman AW, Takimoto-Kamimura M. Acta Crystallogr D Biol Crystallogr 66 918-926 (2010)
  142. Synthesis and biological properties of 2-methylene-19-nor-25-dehydro-1alpha-hydroxyvitamin D(3)-26,23-lactones--weak agonists. Chiellini G, Grzywacz P, Plum LA, Barycki R, Clagett-Dame M, DeLuca HF. Bioorg Med Chem 16 8563-8573 (2008)
  143. Synthesis of 2α-heteroarylalkyl active vitamin d3 with therapeutic effect on enhancing bone mineral density in vivo. Matsuo M, Hasegawa A, Takano M, Saito H, Kakuda S, Chida T, Takagi K, Ochiai E, Horie K, Harada Y, Takimoto-Kamimura M, Takenouchi K, Sawada D, Kittaka A. ACS Med Chem Lett 4 671-674 (2013)
  144. Two-dimensional alanine scanning mutational analysis of the interaction between the vitamin D receptor and its ligands: studies of A-ring modified 19-norvitamin D analogs. Shimizu M, Yamamoto K, Mihori M, Iwasaki Y, Morizono D, Yamada S. J Steroid Biochem Mol Biol 89-90 75-81 (2004)
  145. 2 alpha-(3-hydroxypropyl)- and 2 alpha-(3-hydroxypropoxy)-1 alpha,25-dihydroxyvitamin D3 accessible to vitamin D receptor mutant related to hereditary vitamin D-resistant rickets. Kittaka A, Kurihara M, Peleg S, Suhara Y, Takayama H. Chem Pharm Bull (Tokyo) 51 357-358 (2003)
  146. Enhanced coactivator binding and transcriptional activation of mutant vitamin D receptors from patients with hereditary 1,25-dihydroxyvitamin D-resistant rickets by phosphorylation and vitamin D analogs. Liu Y, Shen Q, Malloy PJ, Soliman E, Peng X, Kim S, Pike JW, Feldman D, Christakos S. J Bone Miner Res 20 1680-1691 (2005)
  147. Metabolic activation of tachysterol3 to biologically active hydroxyderivatives that act on VDR, AhR, LXRs, and PPARγ receptors. Slominski AT, Kim TK, Slominski RM, Song Y, Janjetovic Z, Podgorska E, Reddy SB, Song Y, Raman C, Tang EKY, Fabisiak A, Brzeminski P, Sicinski RR, Atigadda V, Jetten AM, Holick MF, Tuckey RC. FASEB J 36 e22451 (2022)
  148. Nuclear hormone receptors in podocytes. Khurana S, Bruggeman LA, Kao HY. Cell Biosci 2 33 (2012)
  149. Two key proteins of the vitamin D endocrine system come into crystal clear focus: comparison of the X-ray structures of the nuclear receptor for 1alpha,25(OH)2 vitamin D3, the plasma vitamin D binding protein, and their ligands. Mizwicki MT, Norman AW. J Bone Miner Res 18 795-806 (2003)
  150. Creative synthesis of novel vitamin D analogs for health and disease. Kittaka A, Saito N, Honzawa S, Takenouchi K, Ishizuka S, Chen TC, Peleg S, Kato S, Arai MA. J Steroid Biochem Mol Biol 103 269-276 (2007)
  151. Identification of a unique subset of 2-methylene-19-nor analogs of vitamin D with comedolytic activity in the rhino mouse. Nieves NJ, Ahrens JM, Plum LA, DeLuca HF, Clagett-Dame M. J Invest Dermatol 130 2359-2367 (2010)
  152. Metabolism of 20-epimer of 1alpha,25-dihydroxyvitamin D3 by CYP24: species-based difference between humans and rats. Kusudo T, Sakaki T, Abe D, Fujishima T, Kittaka A, Takayama H, Ohta M, Inouye K. Biochem Biophys Res Commun 309 885-892 (2003)
  153. Role of c-Jun-N-Terminal Kinase in Pregnane X Receptor-Mediated Induction of Human Cytochrome P4503A4 In Vitro. Taneja G, Chu C, Maturu P, Moorthy B, Ghose R. Drug Metab Dispos 46 397-404 (2018)
  154. Synthesis and biological evaluation of all A-ring stereoisomers of 5,6-trans-2-methyl-1,25-dihydroxyvitamin D(3) and their 20-epimers: possible binding modes of potent A-ring analogues to vitamin D receptor. Fujishima T, Konno K, Nakagawa K, Tanaka M, Okano T, Kurihara M, Miyata N, Takayama H. Chem Biol 8 1011-1024 (2001)
  155. Enteral calcium infusion used successfully as treatment for a patient with hereditary vitamin D resistant rickets (HVDRR) without alopecia: a novel mutation. Huang K, Malloy P, Feldman D, Pitukcheewanont P. Gene 512 554-559 (2013)
  156. Genomic Study of Cardiovascular Continuum Comorbidity. Makeeva OA, Sleptsov AA, Kulish EV, Barbarash OL, Mazur AM, Prokhorchuk EB, Chekanov NN, Stepanov VA, Puzyrev VP. Acta Naturae 7 89-99 (2015)
  157. Model of three-dimensional structure of vitamin D receptor and its binding mechanism with 1alpha,25-dihydroxyvitamin D(3). Rotkiewicz P, Sicinska W, Kolinski A, DeLuca HF. Proteins 44 188-199 (2001)
  158. Molecular cloning, functional characterization, and evolutionary analysis of vitamin D receptors isolated from basal vertebrates. Kollitz EM, Zhang G, Hawkins MB, Whitfield GK, Reif DM, Kullman SW. PLoS One 10 e0122853 (2015)
  159. NMR assignments of tryptophan residue in apo and holo LBD-rVDR. Sicinska W, Westler WM, DeLuca HF. Proteins 61 461-467 (2005)
  160. Novel nonsecosteroidal vitamin D3 carboxylic acid analogs for osteoporosis, and SAR analysis. Kashiwagi H, Ono Y, Shimizu K, Haneishi T, Ito S, Iijima S, Kobayashi T, Ichikawa F, Harada S, Sato H, Sekiguchi N, Ishigai M, Takahashi T. Bioorg Med Chem 19 4721-4729 (2011)
  161. Phosphorylation of human vitamin D receptor serine-182 by PKA suppresses 1,25(OH)2D3-dependent transactivation. Hsieh JC, Dang HT, Galligan MA, Whitfield GK, Haussler CA, Jurutka PW, Haussler MR. Biochem Biophys Res Commun 324 801-809 (2004)
  162. Analogs of 1alpha,25-dihydroxyvitamin D3 with high potency in induction of osteoclastogenesis and prevention of dendritic cell differentiation: synthesis and biological evaluation of 2-substituted 19-norvitamin D analogs. Shimazaki M, Miyamoto Y, Yamamoto K, Yamada S, Takami M, Shinki T, Udagawa N, Shimizu M. Bioorg Med Chem 14 4645-4656 (2006)
  163. Synthesis and biological activities of new 1alpha,25-dihydroxy-19-norvitamin D3 analogs with modifications in both the A-ring and the side chain. Shimizu M, Miyamoto Y, Kobayashi E, Shimazaki M, Yamamoto K, Reischl W, Yamada S. Bioorg Med Chem 14 4277-4294 (2006)
  164. Transcriptome-Wide Profile of 25-Hydroxyvitamin D3 in Primary Immune Cells from Human Peripheral Blood. Hanel A, Bendik I, Carlberg C. Nutrients 13 4100 (2021)
  165. (10Z)- and (10E)-19-fluoro-1alpha,25-dihydroxyvitamin D3: an improved synthesis via 19-nor-10-oxo-vitamin D. Shimizu M, Ohno A, Yamada S. Chem Pharm Bull (Tokyo) 49 312-317 (2001)
  166. (2S,2'R)-analogue of LG190178 is a major active isomer. Hakamata W, Sato Y, Okuda H, Honzawa S, Saito N, Kishimoto S, Yamashita A, Sugiura T, Kittaka A, Kurihara M. Bioorg Med Chem Lett 18 120-123 (2008)
  167. Efficacy of hybrid vitamin D receptor agonist/histone deacetylase inhibitors in vitamin D-resistant triple-negative 4T1 breast cancer. Bijian K, Kaldre D, Wang TT, Su J, Bouttier M, Boucher A, Alaoui-Jamali M, White JH, Gleason JL. J Steroid Biochem Mol Biol 177 135-139 (2018)
  168. Gene-Regulatory Potential of 25-Hydroxyvitamin D3 and D2. Hanel A, Veldhuizen C, Carlberg C. Front Nutr 9 910601 (2022)
  169. Novel vitamin D3 analogs, 1alpha, 25(OH)2D(3)-26, 23-lactam (DLAMs), antagonize bone resorption via suppressing RANKL expression in osteoblasts. Inada M, Tsukamoto K, Hirata M, Takita M, Nagasawa K, Miyaura C. Biochem Biophys Res Commun 372 434-439 (2008)
  170. Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites. Teske KA, Bogart JW, Sanchez LM, Yu OB, Preston JV, Cook JM, Silvaggi NR, Bikle DD, Arnold LA. Eur J Med Chem 109 238-246 (2016)
  171. A series of nonsecosteroidal vitamin D receptor agonists for osteoporosis therapy. Kashiwagi H, Ono Y, Ohta M, Itoh S, Ichikawa F, Harada S, Takeda S, Sekiguchi N, Ishigai M, Takahashi T. Bioorg Med Chem 21 1823-1833 (2013)
  172. Development of analogues of 1alpha,25-dihydroxyvitamin D3 with biased side chain orientation: methylated des-C,D-homo analogues. Gabriëls S, Van Haver D, Vandewalle M, De Clercq P, Verstuyf A, Bouillon R. Chemistry 7 520-532 (2001)
  173. Differential recruitment of coactivators to the vitamin D receptor transcriptional complex by 1alpha,25-dihydroxyvitamin D3 analogs. Schwinn MK, DeLuca HF. Arch Biochem Biophys 465 443-451 (2007)
  174. Effect of 25-hydroxyl group orientation on biological activity and binding to the 1alpha,25-dihydroxy vitamin D3 receptor. Collins ED, Bishop JE, Bula CM, Acevedo A, Okamura WH, Norman AW. J Steroid Biochem Mol Biol 94 279-288 (2005)
  175. Evolutionary and Functional Diversification of the Vitamin D Receptor-Lithocholic Acid Partnership. Kollitz EM, Zhang G, Hawkins MB, Whitfield GK, Reif DM, Kullman SW. PLoS One 11 e0168278 (2016)
  176. Fluorinated vitamin D analogs to probe the conformation of vitamin D in its receptor complex: 19F-NMR studies and biological activity. Ohno A, Shimizu M, Yamada S. Chem Pharm Bull (Tokyo) 50 475-483 (2002)
  177. Isolation and identification of 2alpha,25-dihydroxyvitamin D3, a new metabolite from Pseudonocardia autotrophica 100U-19 cells incubated with Vitamin D3. Takeda K, Kominato K, Sugita A, Iwasaki Y, Shimazaki M, Shimizu M. Steroids 71 736-744 (2006)
  178. Local motifs involved in the canonical structure of the ligand-binding domain in the nuclear receptor superfamily. Tsuji M. J Struct Biol 185 355-365 (2014)
  179. New derivative of 1alpha,25-dihydroxy-19-norvitamin D3 with 3'-alkoxypropylidene moiety at C-2: synthesis, biological activity and conformational analysis. Glebocka A, Sicinski RR, DeLuca HF. J Steroid Biochem Mol Biol 89-90 25-30 (2004)
  180. Novel A-ring analogs of the hormone 1alpha,25-dihydroxyvitamin D3: synthesis and preliminary biological evaluation. Posner GH, Lee SH, Kim HJ, Peleg S, Dolan P, Kensler TW. Bioorg Med Chem 13 2959-2966 (2005)
  181. Synthesis and biological evaluation of 1α,25-dihydroxyvitamin D3 analogues with aromatic side chains attached at C-17. Liu C, Zhao GD, Mao X, Suenaga T, Fujishima T, Zhang CM, Liu ZP. Eur J Med Chem 85 569-575 (2014)
  182. 2-Methylene analogs of 1alpha-hydroxy-19-norvitamin D3: synthesis, biological activities and docking to the ligand binding domain of the rat vitamin D receptor. Grzywacz P, Plum LA, Sicinska W, Sicinski RR, Prahl JM, DeLuca HF. J Steroid Biochem Mol Biol 89-90 13-17 (2004)
  183. An assessment of protein-ligand binding site polarizability. Nayeem A, Krystek S, Stouch T. Biopolymers 70 201-211 (2003)
  184. Asymmetric catalytic ene-cyclization approach to 2-fluoro-19-nor-1,25-dihydroxyvitamin D(3) A-ring analog with significant transactivation activity. Mikami K, Ohba S, Ohmura H, Kubodera N, Nakagawa K, Okano T. Chirality 13 366-371 (2001)
  185. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Sci Rep 8 8883 (2018)
  186. Design and efficient synthesis of new stable 1alpha,25-dihydroxy-19-norvitamin D3 analogues containing amide bond. Suhara Y, Kittaka A, Ono K, Kurihara M, Fujishima T, Yoshida A, Takayama H. Bioorg Med Chem Lett 12 3533-3536 (2002)
  187. Design and synthesis of tetraol derivatives of 1,12-dicarba-closo-dodecaborane as non-secosteroidal vitamin D analogs. Fujii S, Kano A, Masuno H, Songkram C, Kawachi E, Hirano T, Tanatani A, Kagechika H. Bioorg Med Chem Lett 24 4515-4519 (2014)
  188. Design, synthesis, evaluation, and structure of vitamin D analogues with furan side chains. Fraga R, Zacconi F, Sussman F, Ordóñez-Morán P, Muñoz A, Huet T, Molnár F, Moras D, Rochel N, Maestro M, Mouriño A. Chemistry 18 603-612 (2012)
  189. Differential expression of protein disulfide-isomerase A3 isoforms, PDIA3 and PDIA3N, in human prostate cancer cell lines representing different stages of prostate cancer. Diaz Cruz MA, Karlsson S, Szekeres F, Faresjö M, Lund D, Larsson D. Mol Biol Rep 48 2429-2436 (2021)
  190. Ligand affinity, homodimerization, and ligand-induced secondary structural change of the human vitamin d receptor. Falsone SF, Kurkela R, Chiarandini G, Vihko P, Kungl AJ. Biochem Biophys Res Commun 285 1180-1185 (2001)
  191. Residues of the human nuclear vitamin D receptor that form hydrogen bonding interactions with the three hydroxyl groups of 1alpha,25-dihydroxyvitamin D3. Reddy MD, Stoynova L, Acevedo A, Collins ED. J Steroid Biochem Mol Biol 103 347-351 (2007)
  192. Role of residues 143 and 278 of the human nuclear Vitamin D receptor in the full-length and Delta165-215 deletion mutant. Acevedo A, Stoynova L, Davis K, Solórzano R, Collins ED. J Steroid Biochem Mol Biol 89-90 83-87 (2004)
  193. Synthesis and biological activity of 22-oxa CD-ring modified analogues of 1alpha,25-dihydroxyvitamin D3: cis-perhydrindane CE-ring analogues. Demin S, Van Haver D, Vandewalle M, De Clercq PJ, Bouillon R, Verstuyf A. Bioorg Med Chem Lett 14 3885-3888 (2004)
  194. Synthesis of vitamin D3 derivatives with nitrogen-linked substituents at A-ring C-2 and evaluation of their vitamin D receptor-mediated transcriptional activity. Abe J, Nagai Y, Higashikuni R, Iida K, Hirokawa T, Nagai H, Kominato K, Tsuchida T, Hirata M, Inada M, Miyaura C, Nagasawa K. Org Biomol Chem 10 7826-7839 (2012)
  195. The development of CD-ring modified analogs of 1alpha,25-dihydroxyvitamin D. De Clercq PJ, De Buysser F, Minne G, Schepens W, Vrielynck F, Van Haver D, Vandewalle M, Verstuyf A, Bouillon R. J Steroid Biochem Mol Biol 103 206-212 (2007)
  196. cDNA cloning and mRNA expression of retinoid-X-receptor in the ovary of the shrimp Metapenaeus ensis. Cui J, Wu L, Chan SM, Chu KH. Mol Biol Rep 40 6233-6244 (2013)
  197. 2,2-Functionalized analogues of 1alpha,25-dihydroxyvitamin D3, the potent inducers of cell differentiation. Fujishima T, Kittaka A, Kurihara M, Saito N, Honzawa S, Kishimoto S, Sugiura T, Waku K, Takayama H. J Steroid Biochem Mol Biol 89-90 89-92 (2004)
  198. Affinity labeling of rat cytochrome P450C24 (CYP24) and identification of Ser57 as an active site residue. Omdahl JL, Swamy N, Serda R, Annalora A, Berne M, Rayb R. J Steroid Biochem Mol Biol 89-90 159-162 (2004)
  199. Alanine scanning mutational analysis of the ligand binding pocket of the human Vitamin D receptor. Yamamoto K, Choi M, Abe D, Shimizu M, Yamada S. J Steroid Biochem Mol Biol 103 282-285 (2007)
  200. Design and synthesis of novel 1,25-dihydroxyvitamin D3 analogues having a spiro-oxetane fused at the C2 position in the A-ring. Fujishima T, Nozaki T, Suenaga T. Bioorg Med Chem 21 5209-5217 (2013)
  201. Design, synthesis and biological properties of seco-d-ring modified 1α,25-dihydroxyvitamin D3 analogues. Szybinski M, Sektas K, Sicinski RR, Plum LA, Frelek J, DeLuca HF. J Steroid Biochem Mol Biol 171 144-154 (2017)
  202. Examination of VDR/RXR/DRIP205 Interaction, Intranuclear Localization, and DNA Binding in Ras-Transformed Keratinocytes and Its Implication for Designing Optimal Vitamin D Therapy in Cancer. Jusu S, Presley JF, Williams C, Das SK, Jean-Claude B, Kremer R. Endocrinology 159 1303-1327 (2018)
  203. Case Reports Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) caused by a VDR mutation: A novel mechanism of dominant inheritance. Isojima T, Ishizawa M, Yoshimura K, Tamura M, Hirose S, Makishima M, Kitanaka S. Bone Rep 2 68-73 (2015)
  204. Optimization of histone deacetylase inhibitor activity in non-secosteroidal vitamin D-receptor agonist hybrids. Kaldre D, Wang TT, Fischer J, White JH, Gleason JL. Bioorg Med Chem 23 5035-5049 (2015)
  205. Letter Regulation of the vitamin D receptor by vitamin D lactam derivatives. Asano L, Waku T, Abe R, Kuwabara N, Ito I, Yanagisawa J, Nagasawa K, Shimizu T. FEBS Lett 590 3270-3279 (2016)
  206. Synthesis and biological evaluation of new 6-s-cis locked 1,2,25-trihydroxyprevitamin D3 analogues. Sánchez-Abella L, Fernández S, Verstuyf A, Verlinden L, Ferrero M, Gotor V. Bioorg Med Chem 15 4193-4202 (2007)
  207. The C(19) position of 25-hydroxyvitamin D(3) faces outward in the vitamin D sterol-binding pocket of vitamin D-binding protein. Addo JK, Swamy N, Ray R. Bioorg Med Chem Lett 12 279-281 (2002)
  208. Affinity labeling of the nuclear vitamin D receptor with nonsteroidal alkylating agents. Fernández-Gacio A, Fernández-Marcos C, Swamy N, Ray R. Bioorg Med Chem Lett 13 213-216 (2003)
  209. An analog of 1alpha,25-dihydroxy-19-norvitamin D3 with the 1alpha-hydroxy group fixed in the axial position lacks biological activity in vitro. Sicinski RR, Glebocka A, Plum LA, DeLuca HF. J Steroid Biochem Mol Biol 103 293-297 (2007)
  210. Association of vitamin D receptor gene TaqI, FokI and ApaI variants with arteriovenous fistula failure in hemodialysis patients. Huzmeli C, Bagci G, Candan F, Bagci B, Akkaya L, Kayatas M. J Vasc Access 19 303-310 (2018)
  211. Cell-based and in silico evidence against quercetin and structurally-related flavonols as activators of vitamin D receptor. Lau AJ, Politi R, Yang G, Chang TK. J Steroid Biochem Mol Biol 163 59-67 (2016)
  212. Case Reports Clinical Phenotype in a Toddler with a Novel Heterozygous Mutation of the Vitamin D Receptor. Brar PC, Dingle E, Pappas J, Raisingani M. Case Rep Endocrinol 2017 3905905 (2017)
  213. Dimer and superstructure of the active form of a vitamin D3; 1 alpha,24(R)dihydroxy-vitamin D3 monohydrate, C27O3H44.H2O. Koyano K, Saitoh Y, Oshida J, Takimoto-Kamimura M. Chem Pharm Bull (Tokyo) 49 305-311 (2001)
  214. Effects of 2-substitution on 14-epi-19-nortachysterol-mediated biological events: based on synthesis and X-ray co-crystallographic analysis with the human vitamin D receptor. Sawada D, Kakuda S, Takeuchi A, Kawagoe F, Takimoto-Kamimura M, Kittaka A. Org Biomol Chem 16 2448-2455 (2018)
  215. In Silico Prediction of the Metabolic Resistance of Vitamin D Analogs against CYP3A4 Metabolizing Enzyme. Żołek T, Yasuda K, Brown G, Sakaki T, Kutner A. Int J Mol Sci 23 7845 (2022)
  216. Novel A-ring homodimeric C-3-carbamate analogues of 1alpha,25-dihydroxyvitamin D3: synthesis and preliminary biological evaluation. Oves D, Fernández S, Verlinden L, Bouillon R, Verstuyf A, Ferrero M, Gotor V. Bioorg Med Chem 14 7512-7519 (2006)
  217. Novel Vitamin D Receptor Mutations in Hereditary Vitamin D Resistant Rickets in Chinese. Lim LM, Zhao X, Chao MC, Chang JM, Chang WC, Kao HY, Hwang DY, Chen HC. PLoS One 10 e0138152 (2015)
  218. Novel side chain analogs of 1alpha,25-dihydroxyvitamin D(3): design and synthesis of the 21,24-methano derivatives. Calverley MJ. Steroids 66 249-255 (2001)
  219. Robust osteogenic efficacy of 2α-heteroarylalkyl vitamin D analogue AH-1 in VDR (R270L) hereditary vitamin D-dependent rickets model rats. Nishikawa M, Murose N, Mano H, Yasuda K, Isogai Y, Kittaka A, Takano M, Ikushiro S, Sakaki T. Sci Rep 12 12517 (2022)
  220. Structural changes of vitamin D receptor induced by 20-epi-1alpha,25-(OH)2D3: an insight from a computational analysis. Sicinska W, Rotkiewicz P. J Steroid Biochem Mol Biol 113 253-258 (2009)
  221. Synthesis of 19-norcalcitriol analogs with elongated side chain. Brzeminski P, Fabisiak A, Sektas K, Berkowska K, Marcinkowska E, Sicinski RR. J Steroid Biochem Mol Biol 177 231-234 (2018)
  222. Synthesis of 1alpha,25-dihydroxyvitamin D analogues featuring a S(2)-symmetric CD-ring core. Minne G, Verlinden L, Verstuyf A, De Clercq PJ. Molecules 14 894-903 (2009)
  223. Discrepancy in interactions and conformational dynamics of pregnane X receptor (PXR) bound to an agonist and a novel competitive antagonist. Rashidian A, Mustonen EK, Kronenberger T, Schwab M, Burk O, Laufer SA, Pantsar T. Comput Struct Biotechnol J 20 3004-3018 (2022)
  224. Efficient stable isotope labeling and purification of vitamin D receptor from inclusion bodies. Zhu J, Rao H, Tonelli M, Westler WM, Singarapu KK, Markley JL, DeLuca HF, Assadi-Porter FM. Protein Expr Purif 85 25-31 (2012)
  225. Novel calcitriol analogue with an oxolane group: In vitro, in vivo, and in silico studies. Obiol DJ, Martínez A, Ferronato MJ, Quevedo MA, Grioli SM, Alonso EN, Gómez G, Fall Y, Facchinetti MM, Curino AC. Arch Pharm (Weinheim) 352 e1800315 (2019)
  226. Parallel Chemistry Approach to Identify Novel Nuclear Receptor Ligands Based on the GW0742 Scaffold. Teske KA, Rai G, Nandhikonda P, Sidhu PS, Feleke B, Simeonov A, Yasgar A, Jadhav A, Maloney DJ, Arnold LA. ACS Comb Sci 19 646-656 (2017)
  227. S(N)2' addition/1,2-elimination of dimethylsulfonium methylide with epoxy vinyl sulfones: synthesis of exocyclic cross-conjugated dienyl sulfones. Sikervar V, Fuchs PL. Chem Commun (Camb) 47 3472-3474 (2011)
  228. Specific interactions between vitamin-D receptor and its ligands: Ab initio molecular orbital calculations in water. Takeda R, Kobayashi I, Shimamura K, Ishimura H, Kadoya R, Kawai K, Kittaka A, Takimoto-Kamimura M, Kurita N. J Steroid Biochem Mol Biol 171 75-79 (2017)
  229. Synthesis of 19-norcalcitriol analogs with alkylidene moieties at C-2 based on succinic acid and l-methionine. Fabisiak A, Brzeminski P, Berkowska K, Marcinkowska E, Sicinski RR. J Steroid Biochem Mol Biol 177 235-239 (2018)
  230. The UVB1 Vitamin D analogue inhibits colorectal carcinoma progression. Ferronato MJ, Alonso EN, Gandini NA, Fermento ME, Villegas ME, Quevedo MA, Arévalo J, López Romero A, Rivadulla ML, Gómez G, Fall Y, Facchinetti MM, Curino AC. J Steroid Biochem Mol Biol 163 193-205 (2016)
  231. Vitamin D receptor gene polymorphisms and uterine fibroid incidence in Caucasian women. Ciebiera M, Wrzosek M, Wojtyła C, Zaręba K, Nowicka G, Jakiel G, Włodarczyk M. Arch Med Sci 17 1643-1650 (2021)
  232. Alveolar-Capillary Barrier Protection In Vitro: Lung Cell Type-Specific Effects and Molecular Mechanisms Induced by 1α, 25-Dihydroxyvitamin D3. Xiong J, Kaleja P, Ückert L, Nezaratizadeh N, Krantz S, Krause MF, Fitschen-Oestern S, Seekamp A, Cassidy L, Tholey A, Fuchs S. Int J Mol Sci 24 7298 (2023)
  233. First Experimental Quantitative Charge Density Studies of Advanced Intermediate of Vitamin D Analogues. Wanat M, Malinska M, Kutner A, Woźniak K. Molecules 27 1757 (2022)
  234. Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer. Barbier C, Mansour A, Ismailova A, Sarmadi F, Scarlata DA, Bouttier M, Zeitouni C, Wang C, Gleason JL, White JH. Sci Rep 12 6745 (2022)
  235. News New ligands for defective receptors. Habeck M. Drug Discov Today 8 236-237 (2003)
  236. Structure-activity relationship studies on vitamin D-based selective SREBP/SCAP inhibitor KK-052. Kawagoe F, Mototani S, Mendoza A, Takemoto Y, Uesugi M, Kittaka A. RSC Med Chem 14 2030-2034 (2023)
  237. Synthesis and crystal structure of anhydrous analog of 1,25-dihydroxyvitamin d3. Pietraszek A, Malińska M, Chodyński M, Martynow J, Krupa M, Maruszak W, Woźniak K, Kutner A. J Pharm Sci 102 3925-3931 (2013)
  238. Synthesis of C2-Alkoxy-Substituted 19-Nor Vitamin D3 Derivatives: Stereoselectivity and Biological Activity. Mizumoto Y, Sakamoto R, Nagata A, Sakane S, Kittaka A, Odagi M, Tera M, Nagasawa K. Biomolecules 12 69 (2022)
  239. Synthesis of gamma- and delta-lactones from 1alpha-hydroxy-5,6-trans-vitamin D3 by ring-closing metathesis route and their reduction with metal hydrides. Wojtkielewicz A, Morzycki JW. Steroids 72 552-558 (2007)


Quick links